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Abstract 
Mycotoxins are secondary metabolites produced by fungi that may contaminate 
different foods intended for human consumption, resulting in a widespread exposure 
worldwide. The novel exposome paradigm has the ambition to decipher the different 
environmental insults threating human health throughout the entire lifespan. Given the 
large potential impact of mycotoxins in terms of human exposure and related health 
effects, the ambition of this review is to present this group of chemical compounds and 
the high interest to be included in exposome projects. Furthermore, we also attempt to 
approach the novel exposome paradigm to more traditional disciplines such as 
mycotoxin exposure assessment and mycotoxicology, introducing the new 
methodological challenges and translational needs. Hence, we provide an overview of 
major biomarkers currently developed, biological matrices where these may be found, 
an overview of internal exposure levels and potential co-occurrence with environmental 
chemicals and finally an overview of major health effects with the illustrative example 
of the potent xenoestrogen zearalenol. Conversely, these new approaches may be an 
excellent opportunity to fill many research gaps on mycotoxins research as the 
identification of associations with human health, elucidation of join effect with other 
environmental exposures or the decipher of underlying molecular mechanisms by using 
advanced OMICs technologies. 
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Abstract 55 
Mycotoxins are secondary metabolites produced by fungi that may contaminate different 56 
foods intended for human consumption, resulting in a widespread exposure worldwide. The 57 
novel exposome paradigm has the ambition to decipher the different environmental insults 58 
threating human health throughout the entire lifespan. Given the large potential impact of 59 
mycotoxins in terms of human exposure and related health effects, the ambition of this 60 
review is to present this group of chemical compounds and the high interest to be included in 61 
exposome projects. Furthermore, we also attempt to approach the novel exposome paradigm 62 
to more traditional disciplines such as mycotoxin exposure assessment and mycotoxicology, 63 
introducing the new methodological challenges and translational needs. Hence, we provide an 64 
overview of major biomarkers currently developed, biological matrices where these may be 65 
found, an overview of internal exposure levels and potential co-occurrence with 66 
environmental chemicals and finally an overview of major health effects with the illustrative 67 
example of the potent xenoestrogen zearalenol. Conversely, these new approaches may be an 68 
excellent opportunity to fill many research gaps on mycotoxins research as the identification 69 
of associations with human health, elucidation of join effect with other environmental 70 
exposures or the decipher of underlying molecular mechanisms by using advanced OMICs 71 
technologies. 72 
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Highlights 74 
 75 
 Humans are exposed to complex chemical mixtures including mycotoxins worldwide 76 
 The intake of mycotoxins in food leads as a consequence to the presence of chemical 77 
compounds in biological fluids 78 
  79 
 Exposome projects should include mycotoxins within the panel of targeted 80 
biomarkers 81 
 The knowledge about mycotoxin exposure and effects on humans may be largely 82 
improved through Exposome projects. 83 
 84 
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1. The novel ‘exposome’ paradigm 86 
The exposome concept refers to ‘the totality of environmental exposures from conception 87 
onwards’, proposed to complement the genome with all those factors that may be related with 88 
the human phenotypes and responsible of perturbation of biological processes (Wild et al., 89 
2005). This novel vision involves different levels of complexity and dimensionality, 90 
providing an integrative overview of the relationship between the internal biological 91 
processes and the environment. Environmental external factors include radiation, infectious 92 
agents, chemical contaminants and environmental pollutants, diet, lifestyle factors (e.g. 93 
tobacco, alcohol), occupation and medical interventions. The exposome includes also the 94 
wider social, economic and psychological dimension for instance the education, the 95 
psychological and mental stress, or climate (Rappaport et al., 2011; Wild et al., 2012, 2013). 96 
As a major difference to the genome, the exposome has an extremely dynamic nature, 97 
entailing complex approaches to accurate characterizations and decipher the interplay of 98 
external factors with the biological processes and human health. The limitations and 99 
challenges have been already identified and discussed elsewhere, proposing approaches more 100 
adapted to the readily accessible technologies and financial budgets, transitioning towards 101 
more integrative settings (Siroux et al., 2016).  102 
The exposome concept has been shaped in parallel to the fast development and 103 
implementation of advanced mass spectrometry (MS) and high resolution mass spectrometry 104 
(HRMS) methodologies to biomonitoring. These approaches, within a “targeted” context, 105 
have allowed the accurate screening and characterization of a wide range of known external 106 
chemical exposures or related metabolites at individual level. Furthermore, the 107 
implementation of HRMS to non-targeted metabolomic approaches has also allowed the 108 
development of novel screening framework to massively identify new environmental 109 
exposures but also internal molecules generated by the intermediary metabolism. The 110 
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chemical spectra of molecules in the organism is believed to account for about 40 nutrients, 111 
2,000 intermediary metabolites, 200,000 peptides and 500000 lipids, whereas about 400,000 112 
chemicals are believed to be part of the exposome (Jones, 2016). The diet is a major pathway 113 
of intake of environmental chemicals, including non-nutritive molecules with potentially 114 
harmful properties like pesticides, environmental pollutants or chemicals often underscored, 115 
like mycotoxins. Currently, more than 300 mycotoxins are known, but scientific and 116 
regulatory attention is focused only on a reduced number of major toxins, in terms of known 117 
occurrence and toxicity.  118 
Given the large potential impact of mycotoxins in terms of human exposure and related 119 
health effects, the ambition of this review is to present this group of chemical compounds and 120 
the high interest to be included in exposome projects. Furthermore, we also attempt to 121 
approach the novel exposome paradigm to more traditional disciplines such as mycotoxin 122 
exposure assessment and mycotoxicology, introducing the new methodological challenges 123 
and translational needs. Hence, we provide an overview of main mycotoxins, major 124 
biomarkers currently developed and biological matrices where these may be found. The 125 
present review is an introductory overview about available methods of detection for 126 
mycotoxins biomarkers, hence we refer readers to more comprehensive reviews if interested 127 
in a deeper insight (Escrivà et al., 2017a; Vidal et al., 2018; Warth et al., 2016). We also 128 
provide an overview of internal exposure levels and potential co-occurrence with 129 
environmental chemicals which highlight the interest of studying the effect of complex 130 
mixtures including mycotoxins. Finally, a general overview about major health effects of 131 
mycotoxins is provided with an example of the potent xenoestrogen zearalenol (ZOL) to 132 
illustrate the high interest of considering fungal toxins in exposome-health studies.  133 
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2. Mycotoxins, chemical contaminants produced by fungi 135 
Mycotoxins are natural toxicants produced by a high number of species of different fungal 136 
genera. The main mycotoxigenic species belong to the genera Fusarium, Claviceps, 137 
Alternaria, Aspergillus and Penicillium (Marin et al., 2013). These species need particular 138 
eco-physiological conditions, like temperature and humidity (water activity), to grow and 139 
synthesize these secondary metabolites which have adverse effects in animal and human 140 
health. The main substrates or crops with capacity to support the growth and accumulation of 141 
these toxins are cereals, nuts, oilseeds, dried fruits, coffee and spices, and their by-products. 142 
The contamination can occur throughout the food chain, both in the field and in the post-143 
harvest stage, depending on the species involved. It must be borne in mind that the same 144 
species can produce more than one mycotoxin, such is the case of Fusarium graminearum, 145 
which produces deoxynivalenol (DON) and zearalenone (ZEA), and also that the same 146 
mycotoxin can be produced by several fungal species, such as ochratoxin A (OTA), which is 147 
produced by Penicillium verrucosum, Aspergillus ochraceus and Aspergillus carbonarius. 148 
Mycotoxins are a structurally diverse group of relatively low molecular mass compounds that 149 
can occur in three possible forms: as free or unmodified, as matrix associated and as modified 150 
forms (Rychlik et al., 2014). The free or unmodified mycotoxins describe the basic 151 
mycotoxin structures formed by a high number of fungi in well-known biosynthetic 152 
pathways. Some examples of these mycotoxins are aflatoxin B1 (AFB1), OTA, patulin 153 
(PAT), DON, fumonisin B1 (FB1), and ZEA. Their chemical structures are very diverse. So, 154 
we find microcyclic lactones like ZEA, small lactones condensed with hetero- or alicycles 155 
like PAT, furan derivatives like aflatoxins (AFs), alicyclic compounds like T-2 toxin, among 156 
others. The matrix associated forms are either complexes with matrix compounds or are 157 
physically dissolved or trapped or are covalently bound to matrix components or a 158 
combination of both effects. Examples of this group are the fumonisins (FBs) bound to 159 
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carbohydrates or proteins. The third group known as modified mycotoxins describes any 160 
modification of the basic chemical structure of the molecules. One of these modifications are 161 
produced by plants through conjugation reactions such as the formation of DON-3-glucoside 162 
(DON-3-Glc). Other conjugation reactions are produced by animals such as the formation of 163 
DON-3-glucuronide (DON-3-GlcA) or by fungi as for example the formation of ZEA-14-164 
sulfate. Among the chemically modified mycotoxins it is possible to distinguish between the 165 
thermally formed and non-thermally formed ones. The first group describes the modifications 166 
produced during the thermal process of foods and feeds with the example of norDON A-C. 167 
The second group is formed by degradation products of the mycotoxins produced under 168 
alkaline conditions like DON-sulfonate.  169 
It is necessary to highlight that the routine analysis of foods and feeds usually determines the 170 
free or parent mycotoxins. In order to identify and quantify the modified forms, validated 171 
methods using highly sensitive equipment like LC-MS/MS is necessary. The industries don’t 172 
usually dispose of these facilities mostly because of economic issues. However, there is a 173 
danger related to the ingestion of these modified mycotoxins, particularly because of their 174 
release into the digestive system and the formation of free forms, which toxic action has been 175 
proved already. Thus, the exposure assessment might not be accurate enough due to the 176 
presence of the modified mycotoxins. Another possible scenario is the exceptional case when 177 
the modified form is more toxic than its parent molecule (e.g. α-ZOL possesses a stronger 178 
oestrogenic potency than ZEA) (Frizzell et al., 2011). 179 
3. Biomarkers of mycotoxin exposure 180 
Biomarkers are measurable biochemical or molecular indicators of either exposure (exposure 181 
biomarker) or biological response (effect biomarker) to a mycotoxin that can be specifically 182 
linked to the proximate cause (Baldwin et al., 2011). More specifically, a biomarker is a 183 
biological measure (parent toxins, protein or DNA adducts, glucuronide conjugates… 184 
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measured in urine or plasma/serum) which is correlated with the quantity of xenobiotic 185 
ingested (Table 1). Validation of a biomarker requires demonstration of assay robustness, 186 
intake versus biomarker level, and stability of stored samples. 187 
Biomarkers have contributed largely to understanding the causative role of AFB1 in human 188 
hepatocellular carcinoma (Kensler et al., 2011). These have included both biomarkers of 189 
exposure, based on urinary aflatoxin M1 (AFM1) and serum AFB1-albumin adduct as 190 
markers of internal dose, and a biomarker of effect, based on urinary AFB1-N7-guanine as a 191 
measure of biological effective dose, since DNA adduct formation is the biochemical 192 
mechanism whereby AFB1 exerts its carcinogenic potency. 193 
Traditional biomonitoring studies of internal exposure through urine or plasma analysis of 194 
target chemicals, metabolites, or reaction products are useful to link exposures to health 195 
outcomes. Biologically persistent chemicals are well-characterized with traditional methods, 196 
whereas short-lived chemicals are effectively measured only if the individual is undergoing 197 
continuous or continual exposures or if the timing of exposures is known. In particular, 198 
urinary excretion mainly represents recent mycotoxin intake, whereas measurements in 199 
plasma/serum are more likely to represent long-term exposure. Very often urine is the matrix 200 
of choice, as it is easily collected, however, its limitation is the differing urine excretion 201 
owing to different fluid intakes. This can be addressed partially by normalization for the 202 
creatinine concentration of a urine sample. In exposure studies it is always recommended to 203 
collect 24-h urine. Stability studies revealed that a wide range of target analytes were stable 204 
for 12 h at 25 °C post-collection (Njumbe Ediage et al., 2012), but to avoid fermentation 205 
problems that can alter any of the components of the sample, conservation at 2-4ºC is 206 
recommended.  207 
 208 
Table 1. Biomarkers of mycotoxin exposure.  209 
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Mycotoxin Biomarker Validated Reference 
Aflatoxin B1  AFM1 in urine 
 
Aflatoxin –N7-guanine adduct in urine 
AFB1 in urine 
AF-Alb in plasma 
Yes (1.2-2.2% of 
ingested AFB1)) 
Yes (0.2% of  
ingested AFB1) 
No 
No specified 
Zhu et al (1987) 
 
Groopman and 
Kensler (1993) 
 
Chapot and Wild, 
1991 
Fumonisin B1  FB1 in urine 
 
HFB1 in urine 
Sa/So in plasma 
Yes (0.08-0.5 of 
ingested FB1) 
No 
Yes 
Van der Westhuizen et 
al. (2011) 
Riley et al. (2012) 
Shephard and Van der 
Westhuizen (1998) 
Deoxynivalenol ‘total DON’ (free DON+DON released by b-
glucuronidase) in urine 
DON in urine 
DOM in urine 
Yes 
 
No 
No 
Turner et al. (2008) 
Ochratoxin A OTA in urine 
OTα in urine 
4-OH OTA in urine 
OTA in plasma 
Yes 
No 
No 
Yes 
Gilbert et al. (2001) 
 
 
Breitholtz et al. (1991) 
Zearalenone ZEA+α-zearalenol+ß-zearalenol in urine 
ZEA-14-GlcA in urine 
ZEA–Glu in urine 
ZEA+α-ZOL+ß-ZOL in plasma 
No 
 
 
Yes 
 
 
 
Prelusky et al. (1989) 
Fumonisin B1 FB2 in urine No  
HT-2 toxin HT-2 toxin in urine No  
Citrinin CIT in urine No  
 DH-CIT in urine 
CIT in plasma 
No 
Yes 
 
Blaszkewicz et al. 
(2013) 
T-2 toxin T-2 toxin in urine No  
 210 
4. Analytical methods to identify mycotoxins biomarkers in urine 211 
Traditional biomonitoring implies developing analysis protocols for each mycotoxin. This 212 
multiplies the volume of sample required, and may be slower and more expensive. Most 213 
mycotoxin exposure assessments in developing countries have focused on the AFs and FB1, 214 
while DON and its modified forms were usually monitored in developed countries. Recently, 215 
an increasing number of studies include biomonitoring of a range of mycotoxins, as a result 216 
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of the advent of the latest generation of high performance LC-MS/MS instruments, however, 217 
they rarely include simultaneously contaminants other than mycotoxins.  218 
Traditional biomonitoring of aflatoxins, has been mainly carried out through AFM1 219 
determination in urine. The method of choice has been usually competitive enzyme-linked 220 
immunosorbent assays (ELISA) kits, or IAC clean-up followed by HPLC-FD detection. 221 
UPLC-MS/MS methods are nowadays preferred. In these cases, urine samples are 222 
centrifuged, diluted in IAC column compatible buffers, cleaned up, evaporated to dryness and 223 
suspended before injection in LC-MS/MS (Jager et al., 2014).  224 
Total urinary DON (free DON plus DON-GlcA) has been usually analysed using 225 
immunoaffinity enrichment and liquid chromatography mass spectrometry (LC-MS) 226 
quantification according to Turner et al. (2008). This method includes a β-glucuronidase 227 
treatment of the centrifuged and pH- adjusted sample, and a subsequent clean-up using a 228 
DON IAC column, with final LC-MS detection (Wallin et al., 2013). Based on samples 229 
analysed with or without enzymatic treatment, it has been observed that free DON is 22% of 230 
the total urinary DON (Srey et al., 2014). Gratz et al. (2013b) developed a similar method of 231 
extraction and clean-up, for urine samples analysis for DON+DON-glucuronide and de-232 
epoxy-deoxynivalenol (DOM-1) using an LC-MS/MS for detection.  233 
Exposure to OTA has been traditionally analysed through urine dilution and clean-up using 234 
IAC prior HPLC-FD quantification of OTA and OTα aglycones (Manique et al., 2008; 235 
Duarte et al., 2015). However, the increasing evidence of the presence of OTA glucuronides 236 
has led to the search for an indirect method, i.e. by comparing levels of OTA aglycone in 237 
urines without and after enzymatic hydrolysis. Considerable increases in OTA levels are 238 
found after enzymatic hydrolysis in some urine samples which provides evidence for the 239 
excretion of OTA-conjugates. Thus enzymatic treatment of urine samples with ß-240 
glucuronidase/arylsulfatase is recommended before samples clean-up with IAC (Muñoz et al., 241 
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2017). Analysis of OTA in enzymatically hydrolized urine samples have demonstrated 242 
considerably higher detection frequencies for OTA than when those samples were directly 243 
analysed by LC-MS/MS, even when OTA-8-β-glucuronide is used as standard, as it shows 244 
very low sensitivity for the metabolite compared to detection of OTA (aglycone) due to a far 245 
lower ionization efficiency (Muñoz et al., 2017). This suggests that OTA conjugates may 246 
escape detection when direct (‘dilute and shoot’) methods are applied for urinary biomarker 247 
analysis (Ali et al., 2018). 248 
Regarding fumonisins, IAC or SPE (Oasis
®
 MAX cartridge, Waters, UK, Gong et al., 2008) 249 
clean-up prior detection by HPLC/MS system is preferred. A highly sensitive method has 250 
been optimized for FB1 and FB2 determination in urine using IAC followed by liquid 251 
chromatography with tandem mass detection (Silva et al., 2009a). Urine has been also 252 
analyzed to identify the surrogates of fumonisin exposure sphinganine (Sa) and sphingosine 253 
(So). The most common method of choice is HPLC–FD after prior derivatization with o-254 
phthaldahyde or naphthalene-2,3-dicarboxaldehyde. An optimized method for urine also 255 
included the isolation of exfoliated cells followed b extraction with ethyl acetate prior 256 
derivatization (Silva et al., 2009b). 257 
Nowadays multibiomarker studies are often undergone by using separation by LC and 258 
detection using triple-quadrupole analyzers coupled via an electrospray ionization (ESI) 259 
interface. However, the degree of sample purification greatly differs from one study to 260 
another. An excellent review on the main analytical issues related to multibiomarkers 261 
determination was published by Warth et al. (2013) and also covered by Vidal et al. (2018).  262 
The first multibiomarker studies in human urine involved separated IAC clean-up for each 263 
toxin of interest and pooling of the purified extracts, or using multi-IAC containing a range of 264 
antibodies against the more relevant mycotoxins, AFM1, OTA, FB1 and FB2 (Ahn et al., 265 
2010). Similarly, using IAC concentration, DON, T-2 toxin, HT-2 toxin, ZEA, OTA, AFB1, 266 
P O
 S 
T P
 R
 I N
 T
14 
 
aflatoxin B2 (AFB2), aflatoxin G1 (AFG1), aflatoxin G2 (AFG2), as well as FB1 and 267 
fumonisin B2 (FB2) were analysed in urine by LC-MS/MS (Rubert et al., 2011). AFM1, 268 
OTA, DON, DOM-1, α-zearalenol/β-zearalenol (α-ZOL/β-ZOL) and FB1 were 269 
simultaneously analysed by LC-MS/MS (plus other SPE after IAC for subsequent sample 270 
preparation, Solfrizzo et al., 2011). Another urinary biomarker study applying an LC-MS/MS 271 
method for the simultaneous determination of DON, OTA, FB1, AFB1, ZEA, T-2 toxin and 272 
citrinin (CIT), as well as their main metabolites in human urine, was developed and validated 273 
(Ediage et al., 2012). The urine samples required solvent extraction and SPE clean-up prior to 274 
analysis by LC-MS/MS. Later, a method developed by Njumbe Ediage et al. (2013) covered 275 
seven mycotoxins and several important conjugation and breakdown products (in total 18 276 
analytes). Sample cleanup was optimized in a progressive procedure where urine samples 277 
were extracted with ethyl acetate/formic acid (99:1, v/v) followed by strong anion exchange 278 
(SAX) SPE cleanup of the acidified aqueous fraction. The combined extracts of the 279 
evaporated organic phase and the SAX eluate were injected into the LC-MS/MS system.  280 
Simultaneously, a multi-biomarker method was developed based on the LC-MS ‘dilute-and-281 
shoot’ approach for the direct detection of the 15 most relevant key mycotoxin metabolites in 282 
human urine without extract purification (Warth et al., 2012). This rapid method utilized an 283 
UHPLC system in tandem with a QTrap 5500 LC-MS/MS system equipped with a Turbo 284 
electrospray ionisation source. The urine sample was simply diluted 1:10 with 285 
acetonitrile/water (10:90) and injected directly into the LC-MS/MS system. The resulting 286 
LODs defined as the signal-to-noise ratio of 3:1 were for each analyte as follows: AFM1 287 
(0.05 μg/L), FB1 (0.5 μg/L), FB2 (0.5 μg/L), OTA (0.05 μg/L), DON (4.0 μg/L), DON-3-288 
GlcA (6.0 μg/L), DOM-1 (10 μg/L), NIV (3.0 μg/L), T-2 toxin (2.0 μg/L), HT-2 toxin (20 289 
μg/L), ZEA (0.4 μg/L), zearalenone-14-glucuronide (ZEA-14-GlcA) (1.0 μg/L), α-ZOL (0.5 290 
μg/L), and β-ZOL (0.5 μg/L). Besides the simplification, the advantage of this workflow is 291 
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the full recovery of the polar conjugates such as glucuronides which are frequently lost 292 
during sample cleanup. The disadvantage of the dilute and shoot approach is the need for the 293 
latest state-of-the art triple-quadrupole mass analyzer to achieve the very low LODs required. 294 
Even when these highly advanced instruments are used, only moderate to high exposure is 295 
detectable, rather than very low background levels. Some other authors have used such 296 
‘dilute and shoot’ approach (Abia et al., 2013), using H2O/ACN/FA as dilution solvent 297 
(Gerding et al., 2014), 1% ammonium acetate (Vidal el al., 2016), or just injection without 298 
dilution (Huybrechts et al., 2015). 299 
Interestingly, Shephard et al. (2013) compared results of urine analysis both with sample 300 
clean-up (single and multi-biomarker) and by a ‘dilute-and-shoot’ multibiomarker method. 301 
Firstly, urinary FB1 was separately determined using a tailor-made single target method as 302 
previously described (Gong et al., 2008) (SPE+LC-MS/MS), secondly, DON, AFM1, FB1, α-303 
ZOL, β-ZOL, ZEA and OTA) were determined as previously described (Solfrizzo et al., 304 
2011) (enzymatic treatment +IAC+SPE+UPLC-MS/MS), finally, urine samples were 305 
analysed for the biomarkers FB1, FB2, AFM1, OTA, DON, DON-3-GlcA, DON-15 306 
glucuronide (DON-15-GlcA), DOM-1, nivalenol (NIV), T-2 toxin, HT-2 toxin, ZEA, ZEA-307 
14-GlcA, and α- and β-ZOL using a ‘dilute-and-shoot’ method without prior β-glucuronidase 308 
treatment as previously described (Warth et al., 2012). The single biomarker method detected 309 
FB1 (87% incidence; mean ± standard deviation 0.342 ± 0.466 ng/mg creatinine) and DON 310 
(100% incidence; mean 20.4 ± 49.4 ng/mg creatinine) after hydrolysis with β-glucuronidase. 311 
The multi-biomarker ‘dilute-and-shoot’ method showed only 51% of FB1 positive samples, 312 
with a maximum value of 2.59 ng/mg, and indicated that DON-15-GlcA was predominantly 313 
present. The multi-biomarker method with β-glucuronidase and immunoaffinity clean-up 314 
determined ZEA (100%; 0.529 ± 1.60 ng/mg creatinine), FB1 (96%; 1.52 ± 2.17 ng/mg 315 
creatinine), α-ZOL (92%; 0.614 ± 1.91 ng/mg creatinine), DON (87%; 11.3 ± 27.1 ng/mg 316 
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creatinine), β-ZOL (75%; 0.702 ± 2.95 ng/mg creatinine) and OTA (98%; 0.041 ± 0.086 317 
ng/mg creatinine). Given its higher LOD, lower incidence was reported for the ‘dilute-and-318 
shoot’ method. On the other hand, the tandem clean-up procedure led to higher mean and 319 
medium values than using SPE clean-up only. Low correlation was observed among the 320 
different methods for FB1 detection. Better correlation was found among DON biomarkers of 321 
exposure (either DON or DON glucuronides). Similarly, Solfrizzo et al. (2103) compared 322 
single biomarker methods for DON and FB1 to multibiomarker methods (dilute and shoot 323 
and tandem IAC), and showed good performance of the three methods for DON, but 324 
questionable for FB1. Between the multibiomarker methods, acceptable performance was 325 
observed for DOM-1, AFM1, ZEA, α-ZOL and β-ZOL, but not for OTA. 326 
Recently, Turner et al. (2017) compared Wallin et al. (2013) single method (SM) to Solfrizzo 327 
et al. (2014) multidetection method (MM) for DON and its modified forms. Both methods 328 
measure free DON plus the β-glucuronidase digest of DON glucuronides. A higher number 329 
of samples were <LOQ by using the MM method probably due to increased LOD as a results 330 
of an increase of matrix effect, that is, higher ion suppression. The higher matrix effect could 331 
be due to the use of an SPE column for urine purification. However, mean DON 332 
concentrations were not statistically different (p > 0.05). Although the analytical approaches 333 
used in the two methods are similar, including immunoaffinity enrichment and LC-MS/MS in 334 
both, several important details are different. First, the pH of urine before enzymatic digestion 335 
was adjusted for the SM method but not the MM method. Second, the enzyme used for urine 336 
digestion was different. Third, the volume of urine analyzed was 1 mL for SM and 6 mL for 337 
MM. Fourth, the enrichment for the mycotoxin included a single-antibody column for the SM 338 
method and several distinct antibodies in the columns plus an SPE-OASIS HLB column for 339 
the MM method. Finally, the SM approach included an internal individual standard spiked at 340 
the outset of extraction, whereas the MM used a matrix-assisted calibration adjusting all 341 
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samples as the mean recovery for the method. As DON-glucuronides can represent a 342 
significant portion of the total DON in urine, it is plausible that these analytical differences 343 
may have affected the efficacy of deconjugation of DON-glucuronides.  344 
In the later years, salting-out assisted liquid/liquid extraction methods and dispersive solid 345 
phase extraction methods have also been developed for multiple mycotoxins and metabolites 346 
analysis in urine (Song et al., 2013), linked to either LC-MS/MS or GC-MS/MS analysis 347 
(Rodríguez-Carrasco et al. 2014). That latter GC-MS/MS method has been successfully 348 
applied to a 24 h pilot diet study revealing that DON was the main mycotoxin in diet and 349 
urine among the 15 Fusarium toxins analyzed (Rodríguez-Carrasco et al., 2015).  350 
Recently, some studies have specifically compared different extraction and micro-extraction 351 
techniques for Fusarium mycotoxins applied to human urine, showing that dispersive liquid–352 
liquid microextraction (DLLME) was the most performant compared to salting-out liquid–353 
liquid extraction (SALLE), miniQuEChERS (quick, easy, cheap, effective, rugged, and safe) 354 
methods (Escrivà et al., 2017b). Conversely, SALLE showed better accuracy and precision 355 
than DLLME in combination with GC-MS/MS for the determination of 10 Fusarium 356 
mycotoxins (Rodríguez-Carrasco et al., 2017). 357 
A comparison of relevant multidetection biomarker methods for analysis of mycotoxins in 358 
urine is presented in Table 2. Warth et al. (2012) reviewed the main limitations encountered 359 
in multibiomarker monitoring. A range of analytical challenges were listed.  360 
a) First is the extremely low analyte concentrations present in biological fluids following 361 
dietary exposure, thus sample preparation is crucial to obtain acceptable LODs. However, the 362 
great chemical diversity of analytes (including polar conjugates such as glucuronides which 363 
are frequently lost during common cleanup approaches such as SPE or IAC procedures) 364 
makes it difficult. IAC cleanup allows for high enrichment, however, no conjugates or other 365 
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biomarkers/analytes of interest can be included in a method, and enzymatic hydrolysis should 366 
be performed to include conjugates. On the other hand, the dilute and shoot approach does 367 
not need further pretreatment; however, to overcome matrix effects and interfering matrix 368 
peaks, eluents, the chromatographic gradient, and the dilution factor need to be carefully 369 
optimized.  370 
b) Second, co-eluting matrix components can negatively influence the accuracy of 371 
quantitative methods through ion suppression or enhancement in the ion source. Ion 372 
suppression can be reduced efficiently by careful optimization of the eluents and gradient. 373 
Using internal standards and matrix-matched calibration is critical. 374 
c) Third, there is a lack of authentic reference standards and certified reference materials. 375 
P O
 S 
T P
 R
 I N
 T
19 
 
Table 2. Comparison of the number of detected biomarkers and LODs of relevant multidetection biomarker methods for analysis of mycotoxins 376 
in urine.  377 
Reference AFM1 FB1+FB2 DON OTA ZEA T-2 HT-
2 
Others Clean-up Total 
Rubert et al. 
2011 
 9 10 0.5 3 2 3 AFB1, AFB2, AFG1, AFG2 IAC 11 
Warth et al. 
2012 
0.05 0.4 4 0.05 0.4 1 12 DON-3-GlcA, DOM1, NIV, ZEA-14-GlcA, α-ZOL, β-
ZOL, DON-15-GlcA 
No 15 
Ediage et al. 
2012 
0.15 2.7 4 0.15 0.6 1 40 AFB1, CIT SPE 7 
Ediage et al. 
2013 
0.01 0.01 0.04 0.03 0.1 0.05 0.42 AFB1, DOM1, CIT, α-ZOL, β-ZOL, ochratoxin α 
(OTα), 4-hydroxyochratoxin A (4-OH-OTA), DON–3-
GlcA, HFB1,  
ZEA–GlcA 
SPE 18 
Abia et al. 
2013 
0.05 1 4 0.05 0.4 2 20 DON-3-GlcA, ZEA-14-GlcA, DON-15-GlcA, DOM-1, 
NIV, α-ZOL β-ZOL 
No 15 
Gerding et al. 
2014 
0.025 0.25 0.5 0.1 0.025 0.25 2 Zearalanone (ZAN), α-ZOL, β-ZOL, AFB1, AFB2, 
AFG1, AFG2, dihydrocitrinone (DH-CIT),  enniatin B, 
OTα, DON-3-GlcA, ZEA-14-GlcA, ZAN-14-GlcA, α-
ZOL-14-GlcA, β-ZOL-14-GlcA, and HT-2-4-GlcA 
No 24 
Rodriguez- 
Carrasco et al. 
2014 
  0.12  3 0.5 1 DOM1, 3-acetyl-DON, fusarenone-X (FusX), 
diacetoxyscirpenol (DAS), NIV, neosolaniol , ZAN, α-
zearalanol, ß-zearalanol, α-ZOL, ß-ZOL 
Dispersive 
SPE 
15 
Huybrechts et 
al. 
0.002 0.1 0.2 0.001 0.02 0.01 0.2 AFB1, AFB2, AFG1, AFG2, CIT, OH-CIT, DAS , 
DON-3-GlcA, DON-15-GlcA, 3-ADON, 3-ADON-15-
No, 
except for 
32 
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2015 GlcA, 15-ADON, 15-ADON-3-GlcA, DOM1, DOM1-
GlcA, FusX, OTA, ZEA-14-GlcA, -ZOL, -ZOL-
GlcA, -ZOL-14-GlcA, -ZOL, -ZOL-14-GlcA   
OTA, 
CIT, 
AFM1 
(IAC) 
Vidal et al. 
2016 
  0.5 0.003    OTα DON-3-glucoside, 3-ADON, 
DOM-1  
DON-3-GlcA 
No 8 
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5. Analytical methods to identify mycotoxins biomarkers in blood 378 
Biomonitoring of aflatoxins in blood was initially carried out by directly analyzing this group 379 
of toxins (including AFB1, AFB2, AFG1, AFG2, AFM1, aflatoxin B2a (AFB2a), aflatoxin 380 
BG2a (AFG2a), aflatoxin P (AFP) and aflatoxicol) in serum samples by 2D-TLC, previous 381 
extraction with dichloromethane and purification on a silica gel column (Hatem et al., 2005), 382 
or by RP-HPLC with fluorescence detection, previous extraction of samples with chloroform 383 
and hexane (Lopez et al., 2002).  384 
However, nowadays the determination of the AFB1-albumin (AFB1-Ab) adduct in serum 385 
(adduct formed with the lysine amino acid of albumin) is more frequently used, as it has been 386 
demonstrated that the concentration of this adduct in serum is strongly correlated with 387 
aflatoxin intake, which makes it a very useful exposure biomarker (Wild et al., 1992). 388 
Adducts could be formed not only with AFB1, but also with the other main aflatoxin (AFB2, 389 
AFG1 and AFG2). Besides, the AFB1-Ab adducts presents a half-life in the organism of 390 
around 2-3 months, what makes this compound a good biomarker to reflect exposures over 391 
long periods of time, in contrast to what happens with the AFB1-N7-guanine adduct 392 
biomarker in urine, that better reflects day-to-day variations in aflatoxin intake. Moreover, 393 
AFB1-Ab adducts are stable in serum samples stored at -80 °C for over 25 years, allowing for 394 
re-analysis of archived samples years later (Scholl and Groopman, 2008). 395 
For the analysis of the AFB1-Ab adducts in serum, ELISA seems to be the routine analysis 396 
method; samples are previously digested with pronase, extracted and purified and measured 397 
using a competitive ELISA (Chapot and Wild, 1991; Turner et al., 2007, 2008; Gong et al., 398 
2012; Piekkola et al., 2012; Shirima et al., 2013, 2015; Asiki et al, 2014; Chen et al., 2018). 399 
However, other techniques as RIA (Jiang et al., 2005; Tang et al., 2009), HPLC-FD (Mizrak 400 
et al., 2009; Shuaib et al., 2012) and HPLC with isotope dilution mass spectrometry (IDMS) 401 
(McCoy et al., 2005, 2008) have been also used. 402 
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In relation to FBs, direct detection of FB1 in blood samples has not been considered an 403 
appropriate biomarker, due to its rapid elimination and low oral bioavailability. Taking into 404 
account the effect of FBs on the metabolism of sphingolipids (inhibition of the ceramide 405 
synthase enzyme and increase of intracellular Sa concentration), the ratio between Sa and So 406 
(or between Sa-1-phosphate and So-1-phosphate) in plasma has been considered an indirect 407 
indicator of human FBs exposition, and therefore it has been frequently used. However, this 408 
ratio has been considered useful in studies with animals, but in human exposure studies, when 409 
the level of food contamination is relatively low, wide ranges of Sa:So ratios and bad 410 
correlation coefficients have been observed when linear regression was fitted, which suggests 411 
that this ratio present low sensitivity and imprecision in humans (Cano-Sancho et al., 2010). 412 
The analytical method used to determinate these metabolites frequently included plasma 413 
deproteinization, liquid-liquid extraction, hydrolysis and purification, and HPLC-FD analysis 414 
prior derivatisation with o-phthaldialdehyde (Riley, 1994; Shephard and Van der Westhuizen, 415 
1998; Castegnaro et al., 1998), although use of blood spots, LC-MS determination has also 416 
been used (Riley et al., 2015).  417 
Direct OTA detection in human plasma has been widely used, as OTA binds rapidly and with 418 
high affinity to plasma proteins, constituting therefore a good biomarker of exposure 419 
(Coronel et al., 2010; Lino et al., 2008). The method of choice for detection is the HPLC-FD, 420 
and usual methods of analysis comprise liquid-liquid extraction of plasma samples, for 421 
example with acidified ethyl acetate or other solvents, and analysis by HPLC-FD with 422 
postcolumn confirmation through the formation of OTA-methyl ester (Palli et al., 1999), 423 
purification of acidified plasma samples with a C18 Sep-Pak cartridge and analysis by 424 
HPLC-FD with confirmation through the formation of OTα after carboxypeptidase treatment 425 
of samples (Creppy et al., 2005), and other similar methods (Ali et al., 2018), many of them 426 
using immunoaffinity columns (Ghali et al., 2008). Other methods used included detection of 427 
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ochratoxins in plasma by ELISA (Ueno et al., 1998) or LC/MS/MS (Lau et al., 2000; Medina 428 
et al., 2010; Cramer et al., 2015). 429 
Regarding DON, to date, DON, DON-GlcA and DOM-1 in urine are the preferred 430 
biomarkers for the study of DON exposure. However, several attempts have been made to 431 
find DON biomarkers linked to blood samples. Thus, from studies with rodents, Kim et al. 432 
(2008) have proposed the use of plasma haptoglobin, measured using SELDI-TOF/MS as a 433 
diagnostic biomarker for DON intoxication when this is combined with examining the serum 434 
immunoglobulins. These findings have led to a patent application in Korea (patent reference 435 
number KR100809952B1) protecting a diagnostic kit for the evaluation of toxicity and 436 
exposure for DON using haptoglobin-specific protein. However, different results have been 437 
found in experiments with lactating dairy cows (Kinoshita et al., 2015), and, to date, no data 438 
are available in the case of human blood.  439 
With respect to other mycotoxins few studies have been conducted to assess the presence of 440 
other fungal toxins in human blood. Thus, in the case of ZEA, the presence of this metabolite 441 
or its congeners (α-ZOL, ß-ZOL) has been studied in plasma of patients with breast and 442 
cervical cancer by HPLC and GC (Pillay et al., 2002), whereas Massart et al. (2008) studied 443 
the presence of ZEA and derivatives in the serum of healthy girls and affected by central 444 
precocious puberty, performing an enzymatic treatment of samples with glucuronidase, 445 
followed by purification through a immunoaffinity column and analysis by HPLC-FD. On the 446 
other hand, Fleck et al. (2016) have studied the presence of total ZEA (ZEA plus conjugated 447 
metabolites) and total α-ZOL in serum of pregnant women by UPLC-MS/MS and 448 
electrospray ionization (ESI). 449 
Finally, for CIT, studies on human plasma have been developed by means of an acetonitrile 450 
protein precipitation followed by centrifugation and analysis by HPLC-FD and LC-MS/MS 451 
(Blaszkewicz et al., 2013; Ali et al., 2018). 452 
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Regarding plasma or serum, few studies have carried out on multi-detection analysis of 453 
mycotoxins including multiple mycotoxin biomarkers of different mycotoxins groups in one 454 
sample at the same time, mainly due to the high matrix complexity. Thus, in plasma most 455 
methods have only focused on the analysis of structurally-related mycotoxins belonging to a 456 
single family. 457 
Osteresch et al. (2017) have developed a rapid multi-mycotoxin method, using dried whole 458 
blood spots and dried serum spots, which allows for the simultaneous detection and 459 
quantification of a great variety of fungal toxins by HPLC-MS/MS in less than 10 minutes. 460 
This method is able to detect till 27 mycotoxins, of the following groups (data of LOD in 461 
ng/mL is given): aflatoxins (AFB1: 0.012; AFB2: 0.013; AFG1: 0.021; AFG2:0.037; AFM1: 462 
0.017), Alternaria toxins (alternariol: 0.142; alternariol monomethyl ether: 0.146; altenuene: 463 
0.147), enniatins (A: 0.0016,: A1: 0.0055; B: 0.0012; B1: 0.0044), ochratoxins (OTA/2’R-464 
ochratoxin A: 0.012; OTα: 0.014; 10-hydroxyochratoxin A: 0.015), T-2/HT-2 group (T-2 465 
toxin: 0.227; HT-2 toxin: 1.344; HT-2-4-glucuronide: 0.709), ZEA (0.294) and ZAN (0.273), 466 
CIT (0.066) and DH-CIT (0.268), FB1 (0.521) and beauvericin (0.014), with average 467 
recoveries above 90% in most of the cases. 468 
De Santis et al. (2017) have described a method for the analysis of 8 mycotoxins (AFB1, 469 
AFM1, FB1, OTA, ZEA, DON, DOM-1, and gliotoxin –GLIO–) that combine pronase 470 
treatment of serum samples followed by QuEChERS purification and LC-MS detection. 471 
Limits of quantification were low for AFB1 (0.01 ng/mL), AFM1 (0.22 ng/mL) and OTA 472 
(0.16 ng/mL), but in other mycotoxins were above 5 ng/mL (DON, DOM-1) or 11 ng/mL 473 
(GLIO). The absolute recoveries of the method were not too high, since, with the exception 474 
of AFB1 (82%), all the toxins had recoveries below 63%. 475 
Cao et al. (2018) have also described a method for the quantitative determination of 476 
mycotoxins in human plasma, as well as in other biological matrices (like urine) and animal 477 
P O
 S 
T P
 R
 I N
 T
25 
 
derived foods, by HPLC-MS/MS. This method is valid for the determination of aflatoxins in 478 
human plasma (data of LOD in ng/mL is given) (AFB1: 0.07; AFB2: 0.05; AFG1: 0.13; 479 
AFG2:0.15; AFM1: 0.16), as well as of FBs (FB1: 0.41; FB2: 0.39), sterigmatocystin (0.05), 480 
PAT (0.35), CIT (0.18) and OTA (0.15). Sample preparation consisted in a treatment of 481 
plasma with ß-glucuronidase, deproteinization with acetonitrile/acetic acid and evaporation. 482 
Recently, Slobodchikova and Vuckovic (2018) have described a LC-MS method for the 483 
simultaneous detection of 17 mycotoxins in human plasma. Studied mycotoxins are NIV, 484 
DON, 3-ADON, 15-ADON, T-2 toxin, HT-2 toxin, AFB1, AFB2, AFG1, AFG2, ZEA, ZAN, 485 
α-ZOL, ß-ZOL, α-zeranol, ß-zeranol and fusarenon X (FusX). The method avoids the use of 486 
immunoaffinity columns thanks to a three-step liquid-liquid extraction procedure with ethyl 487 
acetate. LOQ of all mycotoxins ranged from 0.1 to 0.5 ng/mL, except NIV (3 ng/mL). This 488 
method is not suitable for OTA, FB1 and FB2 489 
Covering a smaller number of mycotoxins, Serrano et al. (2015) have developed a method for 490 
the simultaneous determination of enniatins (A, A1, B and B1) and beauvericin in human 491 
plasma by HPLC-MS/MS. The method consisted in the deproteinization of samples with 492 
MeOH/H2O (40/60, v/v) followed by solid phase extraction, using in-house prepared 493 
Carbograph-4 SPE column, and detection by HPLC-tandem mass spectrometry with an 494 
electrospray ion source. Experimental LOD obtained were 10 ng/L for enniatins A1 and B, 20 495 
ng/L for enniatin B1 and beauvericin, and 40 ng/L for enniatin A, and recoveries ranged 496 
between 90 to 120%. 497 
6. Biomarkers of mycotoxins in breast milk 498 
The use of breast milk in biomonitoring studies and epidemiological birth cohort studies is 499 
gaining interest due to the large chemical information contained and the easy collection 500 
methods resulting in a non-invasive and valuable biological matrix. By default, breastfeeding 501 
is considered the “gold-standard” diet for infants, however it has been questioned the 502 
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potential health risk associated when mothers are subjected to contaminated diets. The tight 503 
relationship between blood and breast milk compartments results in high and rapid 504 
transference of lipophilic chemicals, however the transference of mycotoxins from blood to 505 
human breast milk and overall occurrence, has been scarcely explored (Reviewed by Warth et 506 
al., 2016). The high interest of studying the concentrations of harmful chemicals in breast 507 
milk is justified not only by the exploration of mother’s internal exposure levels but also the 508 
external exposure of infants during critical windows of development. The vulnerability is 509 
reflected by the low maximum tolerable levels established in baby foods and infant formulas 510 
by regulatory agencies, which enforce those products to rigorous inspections. Surprisingly, 511 
little effort has been addressed to evaluate the levels of mycotoxins in breast milk and risk-512 
benefits derived from breastfeeding. The preparation of samples commonly involves 513 
immunoaffinity columns, liquid-liquid or solid-phase extraction, and the major methods of 514 
detection are based on ELISA kits, liquid HPLC-FD and LC-MS/MS. Maternal determinants 515 
of AFM1 in breast milk determined by ELISA included the season of collection, education 516 
level, lactation stage or consumption of rice and chocolate (Bogalho et al., 2018). The 517 
implementation of multi-mycotoxin detection methods in breast-milk remains as a major 518 
challenge nowadays, yet few studies have published screening exploratory studies (Andrade 519 
et al., 2013; Rubert et al., 2014). As recently summarized by Warth et al. (2016), most studies 520 
have evaluated the occurrence of AFM1 (Brazil, Cameroon, Columbia, Egypt, Iran, Italy, 521 
Jordan, Kuwait, Nigeria, Serbia, Sudan, Tanzania and Turkey) or OTA and related 522 
metabolites (Chile, Egypt, German, Iran, Italy, Poland, Slovakia, Turkey, Brazil and Chile). 523 
Conversely, few studies have explored the levels of AFB1 (Turkey and Egypt), FB1 524 
(Tanzania) or ZEA (Italy). Most studies exploring AFM1 showed percentages of positive 525 
samples exceeding the 25% of analysed samples and mean concentrations of positive samples 526 
ranged from 0.56 and 44000 ng/L (Warth et al., 2016). These values appear specially 527 
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concerning if we consider the maximum concentration levels set up by the European 528 
Commission in infant formula was 0.025 ng/mL (European Commission, 2006).  529 
7. Internal exposure of general population to mycotoxins.  530 
In the last few years an increasing number of studies have been published on assessment of 531 
exposure to mycotoxins in different countries using biomarkers. Most single biomarker 532 
studies dealt with exposure to AFB1 through AFM1 determination in urine. Moderate to high 533 
frequencies were reported all over the world, depending on the LOD of the methods used. In 534 
general, mean and median values under 0.1 ng/mL were detected in different countries in 535 
Asia, America and Europe. Higher absolute concentrations were reported in some countries 536 
in Africa (up to 3.7 ng/mL) (Smith et al., 2017).  Using direct detection of AFB1 in blood, 537 
values from different studies ranged from 0.08 to 7.4 ng/mL, whereas when the AFB1-538 
albumin biomarker was used the values ranged from not detected to values as high as 268 539 
pg/mg. A good review about these data can be found in Waseem et al. (2014). 540 
Secondly, DON exposure through urine analysis was assessed mainly in European countries, 541 
where frequencies in the range 90-100% were usually reported in urine samples, with 12% 542 
found as free DON and 88% as DON glucuronides (Wells et al., 2016). Mean levels of DON 543 
were around 10 ng/mL, while when total DON was assessed higher levels were reported, and 544 
higher total levels could be over 400 ng/mL (Wells et al., 2016). Several studies confirmed 545 
that a significant percentage of the populations were exposed to levels over the TDI. Lower 546 
frequencies of occurrence were observed in other countries like Bangladesh or Tanzania, 547 
where the different dietary habits may be determinant. 548 
Finally, those studies devoted to OTA in Europe reported widely variable frequencies, but 549 
low general levels (mean under 0.3 ng/mL) (Ali et al., 2018; Wallin et al., 2013; Duarte el al., 550 
2015). In blood, OTA has been detected in a great number of studies, with OTA occurrence 551 
frequently over 74% and usually over 90% (Coronel et al., 2010; Waseem et al., 2014), and 552 
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with a global estimation (derived from a big number of published studies) of minimum, 553 
maximum and mean levels of 0.15, 9.15 and 0.45 ng OTA/mL plasma, respectively (Coronel 554 
et al, 2010). 555 
Differences in nutritional habits and quality of consumed foodstuffs are likely the reason for 556 
interregional variations in mycotoxin excretion.  557 
Regarding multibiomarker studies, as shown in Table 3, DON, OTA and AF were the more 558 
often searched and detected mycotoxins, and they co-occurred in most samples. The 559 
frequencies for DON and OTA were high, but low for AFM1 (in contrast to what observed 560 
using single analysis). Only one study reported frequent exposure to ZEA (Solfrizzo et al., 561 
2014). The detected levels, in general, paralleled those observed in the single biomarker 562 
studies, with high concentration for total DON, followed by FB1, DH-CIT, OTA, total ZEA 563 
and AFM1. Nevertheless, differences in analytical methodology and diversity in available 564 
biomarkers limit comparison of the results. 565 
In contrast to what happens with urine, to date there are not many multimycotoxin studies 566 
conducted in blood (Table 3).  567 
De Santis et al. (2017) studied 8 different mycotoxins (AFB1, AFM1, ZEA, OTA, FB1, 568 
DON, DOM-1, GLIO) in the serum of autistic patients and two control groups (one of 569 
siblings and the other of non-parental persons). In all groups OTA was the prevalent 570 
mycotoxin, with mean prevalence of 82.9% of samples in the whole group and 85.1% in the 571 
autistic. For the rest of mycotoxins, all mean values found were below LOQ. Few samples 572 
showed co-occurrence of different mycotoxins (AFB1, AFM1 and OTA in 4% samples, and 573 
AFB1, AFM1, OTA and GLIO in 2% samples). 574 
The most complete is a recent study by Cao et al. (2018), developed in the People’s Republic 575 
of China, in which the plasma of 30 healthy individuals has been analyzed and compared to 576 
that of 30 hepatocellular carcinoma patients. Eleven mycotoxins were simultaneously 577 
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analyzed by HPLC-MS/MS. In the plasma of control patients the most frequently mycotoxin 578 
found was AFB2 (1.37-3.89 ng/mL; 16.6% samples), followed by AFB1 and 579 
sterigmatocystin (13.3%), and AFG1, AFG2, AFM1, FB1 and FB2 (3.3%). No PAT nor CIT 580 
were found in these samples. Higher percentage of positive samples was found in plasma 581 
from hepatocellular carcinoma patients, with sterigmatocystin being the more frequently 582 
found mycotoxin (1.06-3.23 ng/mL; 40%), followed by AFB1 (33.3%) and AFB2 (23.3%). 583 
However, in plasma AFG1, AFG2, AFM1, OTA and CIT were detected just at the LOD of 584 
the method in both kinds of samples, authors not excluding that these results could be false 585 
positives.586 
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Table 3. Mycotoxins detected in urine and blood/plasma samples through multidetection methods (%positives/mean (ng/mL))  587 
Urine biomarkers 
Reference 
Country (Samples) 
DON DON-GlcA OTA AFM1 ZEA  -ZOL β-ZOL FB1-FB2 DH-CIT  
Gerding et al. 2015 
Haiti (142) 
17/3.2 21/17.0 33/0.109 8/0.06  3/1.46  3/0.44 14/0.49  
Germany (50) 16/2.0 54/11.2 30/0.040 n.d.  n.d.  n.d. 28/0.12  
Bangladesh (95) n.d. n.d. 76/0.203 8/0.06  n.d.  1/- 75/2.75  
Solfrizzo et al. 2014 
Italy (52) 
96/11.89  100/0.144 6/0.068 100/0.057 100/0.077 98/0.090 56/0.055   
Wallin et al. 2015 
Sweden (252) 
63/5.38  51/0.90   21/0.13 18/0.10 6/0.07   
Abia et al. 2013 
Cameroon (175) 
6/- 41/5.49 16/0.09 9/0.05 2/0.22 1/-  3/0.63   
Gerding et al. 2014 
Germany (101) 
29/3.38 82/12.21       12/-  
Heyndrickx et al. 
2015 
Belgium (239) 
37/3.9 100/61.3 35/0.278   0.4/0.005   12/0.752  
Ezekiel et al. 2014 
Nigeria (120) 
0.8/2 5/3.5 28/0.2 14/0.3 0.8/0.3   13/4.6   
Warth et al. 2014 
Thailand (60) 
 12/12.4 2/- 5/0.33       
Blood/serum biomarkers 
Reference 
Country (Samples) 
DON DOM-1 OTA AFB1-
AFB2 
AFG1-AFG2 AFM1 CIT ST PAT ZEA FB1-FB2 GLIO  
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De Santis et al. 
2017 
Italy 
Control group 1 
(35) 
Control group 2 
(18) 
 
 
 
22.9/0.5 
12.5/0.8 
 
 
 
17.1/0.3 
6.3/0.1 
 
 
 
77.1/0.27 
75/0.28 
 
 
 
25.7/0.002 
(AFB1) 
6.3/0.00 
(AFB1) 
  
 
 
45.7/0.07 
31.3/0.06 
    
 
 
8.6/0.1 
0/0 
 
 
 
2.9/0.04 
0/0 
 
 
 
14.3/06 
18.8/10.3 
 
Cao et al. 2018 
PR of China (30) 
  traces 13/0.95-1.78  
(AFB1) 
16.6/1.37-
3.89 (AFB2) 
3.3/0.61 
(AFG1)- 
0.43(AFG2) 
3.3/0.57 traces 13/0.88-
2.05 
n.d.  3.3/1.92 
(FB1) 
3.3/2.03 
(FB2) 
  
 588 
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 589 
Table 4 summarizes the calculated daily intakes from the mycotoxin concentration in urine in 590 
some multibiomarker studies. In summary, between 6 and 29% of the populations considered 591 
were exposed to DON at levels over the TDI, suggesting a medium but worrying risk for the 592 
population, and at the same time they could be exposed to OTA or AFB1 levels of concern. 593 
Since AFB1 is a potent mutagenic carcinogen, no TDI values are established. The presence of 594 
AFM1 in urine samples is of concern. The TDI of 2 μg/kg b.w. for FB1 was never exceeded 595 
by healthy population.  596 
  597 
Table 4. Calculated daily intake from some exposure studies (mean/max/% exceeding TDI). 598 
 DON OTA AFB1 FB1 
Reference (n) TDI  
1 µg/kg bw 
TDI  
0.017 µg/kg bw 
- TDI  
2 µg/kg bw 
Gerding et al. 
2015 
Haiti (142) 
0.27/4.38/6  0.03/0.23/- 0.05/1.74/0 
Germany (50) 0.3/2.15/6  - - 
Bangladesh (95) -  0.03/0.195/- 0.03/1.362/0 
Solfrizzo et al. 
2014 
Italy (52) 
0.59/3.37/6 0.139/2.07/94 0.668/0.142/- 0.274/1.759/0 
Abia et al. 2013 
Cameroon (175) 
HIV sub-
populations 
0.21/2.59/- 0.004/0.094/- 0.0425/1.15/- 5.25/123.3/- 
Gerding et al. 
2014 
Germany (101) 
0.52/5.67/12    
Heyndrickx et al. 
2015 
Belgium (239) 
1.24/10.08/29 0.001/0.021/1   
 599 
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Multi-detection methods have allowed assessing the levels of co-exposure to different 600 
mycotoxins by an individual through urine analysis. Consequently, it has been confirmed that 601 
co-occurrence of two toxins in a urine sample is usually common (more than single 602 
contamination), however results depend highly on the analysed toxins, if only parent 603 
mycotoxins were analysed, 1-2 toxins are usually reported, while if both parent and modified 604 
mycotoxins are analysed 2 to 4 toxins are usually found in a sample. Moreover, lower LOD 605 
of the methods led to higher reported co-occurrence. For example, Gerding et al. (2015) 606 
reported that between 16-54% samples contained two detectable toxins, between 6 and 20 607 
samples contained 3 toxins and 1-2% contained 4 toxins. DH-CIT and OTA usually co-608 
occurred as well as DON and DON-GlcA, and also 3 of them. Fusarium toxins and OTA 609 
have been also shown to occur (Wallin et al., 2015), for example, DON, ZEA, OTA and 610 
DON, ZEA, FB1, OTA, co-occurred in 38 and 52% of urine analysed samples (Solfrizzo et 611 
al., 2014). Studies on exposure in Cameroon reported 4% co-exposure to AFM1 and DON, 612 
3% to OTA and DON and 5% to DON and NIV (Abia et al., 2013). 613 
8. Co-exposure of mycotoxins with other environmental chemicals 614 
A major research gap is the potential concurrent exposure of mycotoxins with other 615 
environmental chemicals that may exhibit some interactive activity and/or exert some 616 
biological function converging in the same molecular pathways. As far as we know, there are 617 
not biomonitoring studies exploring the simultaneous presence of a panel of environmental 618 
chemicals including some type mycotoxin. However, the estimates relying on dietary 619 
exposure modelling suggest that multiple patterns of co-exposure are likely within general 620 
population. The research on mixture identification from the second French Total Diet Study 621 
revealed the extended exposure to mycotoxins in complex mixtures with other environmental 622 
chemicals in most of French diet clusters. For instance, a first cluster containing 18% of the 623 
whole population, was expected to have a significantly higher exposure to mycotoxins (HT-2 624 
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toxin, DON, ZEA and NIV), polycyclic aromatic hydrocarbons (PAHs) (pyrene and 625 
phenanthrene) and bisphenol A, than the whole population. The estrogenic ZEA was also 626 
identified in another cluster with many PAHs, acrylamide, trace elements, pesticides and the 627 
sum of eight polybrominated diphenyl ethers in a cluster representing the 21% of the 628 
population with dietary habits related to junk food and identified as “Snacking” (Traore et al., 629 
2016). Using a similar approach based on the identification of consumption systems 630 
integrated with exposure data, different clusters of pregnant mothers from the two large 631 
French cohorts “Étude Longitudinale Française depuis l’Enfance” (ELFE) and “L’étude des 632 
déterminants pré et post natals du développement et de la santé des enfants” (EDEN), were 633 
identified to be more exposed to mycotoxins simultaneously with other environmental 634 
chemicals. The model was comprehensive including 210 chemicals of which 18 were major 635 
mycotoxins or parent compounds. The “Myco-Pest-PAH” mixture identified from EDEN 636 
before pregnancy was also found in EDEN during pregnancy. It contained eight mycotoxins 637 
(α-ZAL, α-ZOL, diacetoxyscirpenol (DAS), DON-3-GlcA, FusX, OTB, OTA and HT-2 638 
toxin), three pesticides (chlorpyrifos-methyl, cyproconazole and pirimiphosmethyl) and four 639 
PAHs (benzo[g,h,i]perylene, benzo[e]pyrene, cyclopenta(c,d)pyrene and indeno[1,2,3-640 
cd]pyrene). In EDEN before pregnancy, these substances were associated with nine other 641 
pesticides (pyriproxyfen, tetradifon, sulphur, chlorothalonil, diethofencarb, flutriafol, 642 
iprodione, ethion and bifenthrin) and an additive (sulphites). In EDEN during pregnancy, 643 
these substances were associated with three other mycotoxins (DON, DON-15-GlcA and 644 
ZEA), a PAH (pyrene), two phytoestrogens (daidzein and genistein), a trace element 645 
(gallium), a pesticide (sulphur) and two perfluoroalkyl acids, perfluorobutane sulfonate and 646 
perfluorohexanesulfonic acid (Traore et al., 2018). Despite the uncertainties related to the 647 
dietary modelling methodologies, these results provide strong evidence concerning the 648 
potential co-exposure of highly bioactive mycotoxins like -ZEA with many environmental 649 
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chemicals during highly sensitive developmental windows. These modelling studies provides 650 
also light on the potential weight of mycotoxins in the human chemical exposome, as 651 
suspected by the extensive occurrence of mycotoxins in diets.  652 
These profiles extracted from a European diet only represent a region where strict mycotoxin 653 
control regulation is enforced, underscoring the weight of mycotoxins in the chemical 654 
exposome of population in developing countries. The “traditional” fungal contamination of 655 
cereals with the mycoestrogen ZEA, has been identified as a major public health challenge 656 
co-existing with emerging chemical exposures resulting of unstructured industrial 657 
development resulting on high exposures to lead, air pollution, pesticides or e-waste by-658 
products (Bornman et al., 2017).  659 
 660 
We have failed to find in the literature examples of targeted approaches that use liquid or gas 661 
MS methods for the simultaneous detection of mycotoxins and environmental contaminants 662 
in biological specimens. An inspiring example is the method developed by LC-MS with 663 
previous SPE for the simultaneous determination of mycotoxins (AFB1, OTA and PAT) and 664 
bisphenol A in food matrices that could be adapted and applied for urine samples (Song et al., 665 
2013). Novel analytical workflows based on HRMS untargeted metabolomic approaches may 666 
become efficient solutions to overcome existing analytical challenges for the screening of 667 
large panel of chemicals including well-known chemicals. A proof-of-concept study has 668 
recently presented a novel workflow for analysis of blood and urine based on HPLC coupled 669 
to Bruker Impact II quadrupole time-of-flight (Q-TOF) mass spectrometer with a previous 670 
simple sample preparation (Warth et al., 2017). The panel of detected features are further 671 
explored using machine-learning algorithms combined to the XCMS/METLIN platform to 672 
elucidate the pathways related to the annotated signature. Through the pilot study the authors 673 
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demonstrated to efficiently identify low concentrations of common xenoestrogens such as 674 
genistein, ZEA and triclosan at in commercial biological matrices. 675 
9. Mycotoxins and human health effects 676 
The disease caused by mycotoxins is called mycotoxicosis. Mycotoxins can be a threat to 677 
both animal and human health. Oral ingestion of contaminated food is the most frequently 678 
exposure way, however dermal contact and inhalation can also occur (Marin et al., 2013). 679 
Their toxic effect depends on the toxicity of each mycotoxin, the extent of exposure, age and 680 
nutritional status of the individual and possible synergistic effects with other chemicals that 681 
the individual is exposed. Infants is considered the most vulnerable population group due to 682 
the relative inefficiency of detoxification pathways and high relationship of between internal 683 
doses per body weight. 684 
There are more than 300 known mycotoxins which are suspected of widely differing modes 685 
of action, however formal toxicological evaluation and comprehensive risk assessment have 686 
been conducted only for environ 10 of most known or major mycotoxins. Consequently, very 687 
little is known about the potential toxicological and biological effects of secondary 688 
mycotoxins, metabolites or emerging mycotoxins. 689 
To date, most toxicological evaluation is based on experimental studies, including in vitro 690 
and in vivo studies, conversely the body of evidence from human studies is limited to few 691 
epidemiological studies or case studies conducted shortly after human mycotoxicosis 692 
outbreaks. An overview of major health effects of mycotoxins at different toxicological levels 693 
is summarized at Table 5, nonetheless readers may find more detailed reviews published in 694 
the literature (Bui-Klimke et al., 2015; EFSA 2017; Kensler et al., 2011; Marin et al., 2013; 695 
Peraica et al., 1999; Puel et al., 2010). 696 
Table 5. Overview of major health effects of mycotoxins at different toxicological levels.  697 
Mycotoxin 
group 
Interaction 
Nuclear Receptor 
Cellular 
responses 
Health 
effects 
Animals 
Health 
effects 
Humans 
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AFB1  
AFM1 
Pregnane X 
receptor  
Constitutive 
androstane receptor 
Aryl hydrocarbon 
receptor  
Vitamin D receptor 
Formation of DNA 
adducts 
Lipid peroxidation 
Bioactivation by 
cytochromes P450 
Conjugation to GS-
transferases 
Hepatotoxicity 
Genotoxicity 
Carcinogenicity 
Immunomodulation 
Cancer 
Impaired child growth 
FB1 - Inhibition of ceramide 
synthesis 
Adverse effect on the 
sphinganine/sphingosine 
ratio 
Adverse effects on the cell 
cycle. 
Central nervous system 
damage 
Hepatotoxicity 
Genotoxicity 
Immunomodulation 
Oesophageal cancer 
Liver cancer 
Neural tube defects 
Impaired child growth 
OTA - Effect on protein 
synthesis. 
Inhibition of ATP 
production 
Detoxification by 
peptidases 
Nephrotoxicity 
Genotoxicity 
Immunomodulation 
Nephritic syndrome 
BEN 
 
PAT Ø Indirect enzyme inhibition 
In vitro mutagenesis 
Neurotoxicity 
Immunotoxicty 
Disruption of barrier 
function 
 
- 
DON 
NIV 
T-2 toxin 
HT-2 toxin 
Peroxisome 
proliferator-
activated receptor 
Liver X receptor 
Retinol X receptor 
G-protein coupled 
receptor 
Apoptosis  
Oxidative stress 
Inhibition protein 
synthesis 
 
Hematotoxicity 
Immunomodulation 
Skin toxicity 
Anorexia and vomiting 
Reduced weight gain 
Disruption of barrier 
function 
 
Hormone-dependent 
cancer 
Acute mycotoxicosis 
ZEA 
ZOL 
Estrogen Receptor-
and - 
Binding to oestrogen 
receptors 
Bioactivation by 
reductases 
Conjugation to 
glucuronyltransferases 
Reproductive adverse 
effects 
Thelarche 
Precocious puberty 
Breast cancer  
 698 
Among the toxicological initiating events, the interaction of most mycotoxins with nuclear 699 
receptors has been scarcely explored (reviewed by Dall’Asta, 2016). The exception is the 700 
case of ZEA and ZOL whose potent actions to activate the oestrogen receptor pathway and 701 
trigger endocrine perturbations merits an entire section presented hereafter. AFB1 has been 702 
found to modify the expression of nuclear receptors such as pregnane X receptor (PXR), 703 
constitutive androstane receptor (CAR), and aryl hydrocarbon receptor (AhR) at 704 
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transcriptional level, and also causing the downregulation of vitamin D receptor. Hormone 705 
exocytosis caused by DON was found to be triggered by G-protein coupled receptor (GPCR)-706 
mediated Ca2
+
 signaling, using the murine neuroendocrine tumor STC-1 cell line (Zhou and 707 
Pestka, 2015). PAT has been evaluated against different endocrine disrupting models and no 708 
studies have revealed effects on reporter gene assays at the receptor level. 709 
A broad range of adverse health effects have been identified for mycotoxins in animals and 710 
humans, including hepatotoxicity, estrogenicity, immuno/haematotoxicity, nephrotoxicity or 711 
neurotoxicity. And some of them are recognized as genotoxic and/or carcinogenic, including 712 
AFB1, one of the most carcinogenic food contaminants in human diets and classified as 713 
carcinogenic to humans by the International Agency for Research on Cancer (Group 1), or 714 
OTA and FBs classified as possible carcinogens (Group 2B). AFB1 is a primary cause of 715 
human hepatocarcinoma, and in developing countries it acts synergistically with the hepatitis 716 
B virus infection.  717 
Mycotoxins also affects the intestinal barrier function, impairing the permeability and 718 
integrity of epithelial cells. Most prominent effects have been document for the trichothecene 719 
DON that may strongly impair the expression, localization and function of tight junction 720 
proteins which seal the epithelial monolayer and prevents the para-cellular diffusion of 721 
luminal antigens and microorganisms. Other trichotecenes including T-2 and HT-2 toxin and 722 
mycotoxins such as PAT or FB1 have been found to impair some of the physiological 723 
parameters that characterize the intestinal barrier function (Akbari et al., 2017). On this basis, 724 
it has been hypothesized the role of mycotoxins in the pathophysiology of chronic intestinal 725 
inflammatory diseases, such as inflammatory bowel disease, and in the prevalence of food 726 
allergies. 727 
The potential effect of mycotoxins in infant growth parameters has been recognised as a 728 
priority research gap, especially in developing countries, where the high occurrence of 729 
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mycotoxins comes together with the high prevalence of intrauterine growth restriction, infant 730 
and young stunting, underweight wasting. Whereas no epidemiological studies have been 731 
conducted to evaluate the associations between exposure to DON or ZEA and infant growth 732 
parameters, some studies that analysed exposure to AFs and FBs consistently found negative 733 
associations (Lombard et al., 2014). For instance, in African countries, strong dose response 734 
relationships were found between exposure in utero and/or early infancy to AFs and growth 735 
retardation, identified by reduced birth weight and/or low weight-for-age or height-for-age Z 736 
scores (Turner et al., 2013). 737 
Another important aspect to be considered is that many foods can present a simultaneous 738 
presence of different food contaminants, like mycotoxins, pesticides, heavy metals or 739 
radioactive particles (Kosalec et al., 2009). This multi-contamination can strongly modify the 740 
toxic effects of some of them resulting in a range of interactive effect as demonstrated by the 741 
simultaneous exposure of Caco-2 cells and HEK-293 kidney cells to cadmium and DON (Le 742 
et al., 2017). The toxicological evaluation of combinations of mycotoxins for the 743 
characterization of potential interactions is an emerging and very active field of research 744 
(Alassane-Kpembi et al., 2017). 745 
 746 
10. Mycotoxins as endocrine disruptors: case of ZEA and its derivatives 747 
The Endocrine Society’s Scientific Statement on Endocrine-Disrupting Chemicals (EDCs) 748 
says that an EDCs is “an exogenous chemical, or mixture of chemicals, that interferes with 749 
any aspect of hormone action” (Gore et al., 2015). The particular mechanism of actions of 750 
EDCs represent a novel paradigm in chemical risk assessment introducing new challenges 751 
related to ability of inducing biological effects at very low concentrations or the presence 752 
non-monotonic dose-responses. Hence, the emerging concern with EDCs emphasize the high 753 
interest of including mycotoxins, specially ZEA and its metabolites within the panel of 754 
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targeted analytes in exposome projects addressing hormone-dependent diseases. Despite the 755 
knowledge about the endocrine disrupting action of ZEA and its strong oestrogenic effects 756 
was identified decades ago (recently reviewed by Kowalska et al., 2016 and Metzler et al., 757 
2010), little attention has been paid by most researchers on EDCs who has extensively 758 
focused on industrial compounds such as bisphenol A or phthalates. Occurrence studies have 759 
demonstrated the pervasive presence of ZEA in cereal-based foods and the extended exposure 760 
among general population supporting that ZEA and specially the metabolite ZOL may be a 761 
relevant contributor on the total body burden of xenoestrogenic activity.  762 
In silico and in vitro studies have demonstrated the high affinity of ZEA and ZOL to bind and 763 
activate estrogen receptor, exhibiting potencies similar to 17-estradiol, and substantially 764 
higher than many industrial xenoestrogens such as bisphenol A (See Figure 1, based on 765 
Kuiper et al., 1998). Metabolite ZOL has non-estrogenic chemical structure but resembles 766 
that of 17-estradiol, exhibiting similar key contacts in the binding pocket of ER, resulting 767 
on high bioactivity (Delfosse et al., 2014; Balaguer et al., 2017). For that reason, a-ZON is 768 
recognised as one the most active xenoestrogens that can modulate ER activity at 769 
concentrations as low as 0.1 nM. (Balaguer et al., 2017). 770 
Figure 1. Relative transactivation activity of environmental endocrine disruptors for 771 
estrogenic receptor alpha created from data published by Kuiper et al., (1998). ZEA appears 772 
highlighted in red.  773 
 774 
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The related effects of ZEA and its derivatives in cells include the stimulation of growth of 775 
estrogen receptor-positive human breast cells, stimulation of cell cycle progression of MCF-7 776 
cells (Metzler et al., 2010). It has been also shown that ZEA may affect the metabolism of rat 777 
adipocytes, including the stimulation of basal lipolysis and reduced epinephrine stimulated 778 
lipolysis (Kandulska et al., 1999), suggesting ZEA also as a metabolic disruptor candidate.  779 
The endocrine disrupting effects of ZEA in animals includes the impairment of reproduction, 780 
uterotropic activity, hyperoestrogenism and inflammation of the vagina, endocrine-disruptive 781 
effects during gestation and neonatal life vaginal cornification, persistent estrus, reduced 782 
fertility, anovulation and decreased gonadotropic hormone output by the hypophysis among 783 
others (Kowalska et al., 2016; Metzler et al., 2010). Despite the large evidence suggesting the 784 
potential hormone disrupting effects of ZEA, few epidemiological studies have been 785 
conducted in humans to explore associations with estrogen-dependent diseases. Food 786 
contaminated with ZEA and its natural metabolites was associated with the development of 787 
precocious puberty, a risk factor for breast cancer (Gray et al., 2017). Furthermore, higher 788 
urinary ZEA levels, resulting from recent intake of beef or popcorn, were inversely 789 
associated with the onset of breast development (Bandera et al., 2011).  790 
 791 
11. Mycotoxins within the human exposome: challenges and opportunities 792 
The mycotoxins constitute a large group of chemicals that can be found regularly in foodstuff 793 
worldwide often resulting in the chronic exposures of low doses of complex mixtures of 794 
mycotoxins concurrently with industrial chemicals, phytochemicals and nutrients as 795 
represented in the Figure 2. The fast excretion and the low concentration levels of 796 
mycotoxins challenge their detection in biological samples, however current evidence 797 
demonstrate that major mycotoxins can be commonly found within the urine and blood 798 
chemical spectra (Marin et al., 2013). Dietary exposure assessment studies support that 799 
P O
 S 
T P
 R
 I N
 T
42 
 
infants and children are the most exposed population groups and the mycotoxin exposures 800 
continue through the entire life. Despite the relevance in terms of exposure and health effects, 801 
mycotoxins are often underscored and/or overlooked in epidemiological research as 802 
acknowledged by the visionary Christopher Wild (Wild and Gong, 2009), and no attention 803 
have received by major exposome projects launched in Europe, such as the impressive 804 
HELIX or EXPOsOMICS projects. 805 
Figure 2. Conceptual representation of the mycotoxin compartment within the human 806 
exposome framework including the sum of the most important mycotoxins that may found in 807 
the diet and respective forms or metabolites that are used as biomarkers in blood and urine. 808 
 809 
 810 
 811 
The novel exposome paradigm proposes a chemical-agnostic approach, that appears as an 812 
excellent opportunity to evaluate the role of mycotoxins in human health through more 813 
integrative approaches. This approach contrasts with the historical expertise of scientist that 814 
have been focusing on specific chemicals or group of chemicals. Hence, it looks like a big 815 
communicative and cross-talk effort will be required to efficiently optimize the already 816 
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available knowledge across disciplines. For instance, the mycotoxin compartment of human 817 
exposome, has been pretty well characterized for the main mycotoxins in terms of exposure 818 
and health effects, despite little is known about the rest of mycotoxins, modified forms and 819 
more emerging toxins. 820 
To date, most mycotoxin exposure assessment studies have been based on dietary modelling 821 
approaches although many limitations exist on these indirect exposure assessment methods, 822 
especially if we consider the uncertainties related to these modelling methods, and also the 823 
intra-individual or seasonal variability. Hence biomonitoring methods are considered the 824 
‘gold-standard’ to evaluate the individual exposures, however the field is still on its 825 
emergence and few biomarkers have been fully validated. The biomonitoring studies applied 826 
to mycotoxins have been mainly focused on surveillance of general population with 827 
regulatory or risk assessment purposes and few epidemiological studies have considered the 828 
evaluation of mycotoxins. Methodological approaches used to detect the mycotoxin 829 
biomarkers will strongly determine the performance (e.g. sensitivity), resulting on 830 
dramatically different results depending on the detection/quantification thresholds achieved 831 
(p.e. direct vs indirect methods). The development of reliable, accurate and sensitive 832 
multibiomarker methods to simultaneously characterize a large panel of mycotoxins, but also 833 
industrial pollutants, will strongly help to understand the potential associations between 834 
environment and health. On this sense, the application of non-targeted or semi-targeted 835 
HRMS metabolomic methods appears as a promising screening approach to identify exposure 836 
risk factors, and related biomarkers of biological perturbation (Warth et al., 2017). It appears 837 
also as a great opportunity to explore the underlying toxicological effects of mycotoxins in 838 
humans. Coupling other OMICs platforms for the identification of endogenous chemical 839 
signatures we may gain access to early biomarkers of health effects and biological 840 
perturbation triggered by mycotoxins. In any case, a list of challenges associated with the 841 
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accurate determination of biomarkers of non-persistent pollutants exposure applies directly to 842 
the mycotoxins, including the high intra- and inter-day individual variability, requiring 843 
repeated sampling protocols to avoid the exposure misclassification (Perrier et al., 2016). 844 
Additionally, specific issues related to mycotoxins such as the variability related to seasonal 845 
or weather influences on mycotoxin productions will challenge the estimations of individual 846 
trajectories. 847 
The simultaneous determination of mixtures of mycotoxins within more complex cocktails of 848 
environmental pollutants will allow address major research gaps related to mixture effects. A 849 
growing interest on the effect of mycotoxin mixtures have led toxicologist dosing binary and 850 
tertiary combinations of mycotoxins, sometimes with little similarities on mechanism of 851 
action, whereas few or non-studies have evaluated the simultaneous effect of mycotoxins 852 
with other environmental pollutants with similar biological actions (e.g. the xenoestrogens 853 
bisphenol A and ZEA). 854 
  855 
12. Concluding remarks 856 
In the present review we have shown that mycotoxins maybe commonly found at high 857 
concentrations in blood and urine from individuals from developing countries, but also 858 
frequently found at moderate or low concentrations in developed regions. For instance, it has 859 
been estimated that 500 million of the poorest people in sub-Saharan Africa, Latin America, 860 
and Asia are exposed to mycotoxins at levels that substantially increase mortality and severe 861 
diseases (Wild and Gong, 2010). The health effects of mycotoxins are very wide, targeting 862 
different toxicological endpoints, biological functions and have been related with multiple 863 
diseases. To date, few studies have been able to demonstrate consistent associations of health 864 
effects in humans relying most of studies on animal or in vitro settings.  865 
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We strongly believe that mycotoxins represent a relevant component of the human exposome 866 
and that exposome-based projects aiming to explore the role of chemical exposome on human 867 
health, should strongly consider the mycotoxins within the panel chemical candidates.  868 
Whereas industrial chemicals may be banned and set out of the market, mycotoxins will not 869 
be completely removed of raw foods and food items intended for human consumption. Even 870 
with very stringent regulations, humans will continuously be exposed to low level of 871 
mycotoxins whose combined effect and their combined effect with other environmental 872 
exposures whose effects are completely unknown. As we have shown in this document, 873 
currently there are available robust and accurate analytical methods that allow the 874 
identification and characterization of multiple mycotoxins and/or their metabolites in most 875 
common biological samples, allowing the direct implementation in epidemiological research.  876 
Overall, we acknowledge that the exposome projects will be a great opportunity to better 877 
translate the knowledge generated on mycotoxicology during the past decades in 878 
environmental health. Conversely, these new approaches may be an excellent opportunity to 879 
fill many research gaps on mycotoxins research as the identification of associations 880 
mycotoxins with human health, elucidation of join effect with other environmental exposures 881 
or the decipher of underlying molecular mechanisms by using advanced OMICs technologies.  882 
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Abstract 55 
Mycotoxins are secondary metabolites produced by fungi that may contaminate different 56 
foods intended for human consumption, resulting in a widespread exposure worldwide. The 57 
novel exposome paradigm has the ambition to decipher the different environmental insults 58 
threating human health throughout the entire lifespan. Given the large potential impact of 59 
mycotoxins in terms of human exposure and related health effects, the ambition of this 60 
review is to present this group of chemical compounds and the high interest to be included in 61 
exposome projects. Furthermore, we also attempt to approach the novel exposome paradigm 62 
to more traditional disciplines such as mycotoxin exposure assessment and mycotoxicology, 63 
introducing the new methodological challenges and translational needs. Hence, we provide an 64 
overview of major biomarkers currently developed, biological matrices where these may be 65 
found, an overview of internal exposure levels and potential co-occurrence with 66 
environmental chemicals and finally an overview of major health effects with the illustrative 67 
example of the potent xenoestrogen zearalenol. Conversely, these new approaches may be an 68 
excellent opportunity to fill many research gaps on mycotoxins research as the identification 69 
of associations with human health, elucidation of join effect with other environmental 70 
exposures or the decipher of underlying molecular mechanisms by using advanced OMICs 71 
technologies. 72 
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Highlights 74 
 75 
 Humans are exposed to complex chemical mixtures including mycotoxins worldwide 76 
 The intake of mycotoxins in food leads as a consequence to the presence of chemical 77 
compounds in biological fluids 78 
  79 
 Exposome projects should include mycotoxins within the panel of targeted 80 
biomarkers 81 
 The knowledge about mycotoxin exposure and effects on humans may be largely 82 
improved through Exposome projects. 83 
 84 
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1. The novel ‘exposome’ paradigm 86 
The exposome concept refers to ‘the totality of environmental exposures from conception 87 
onwards’, proposed to complement the genome with all those factors that may be related with 88 
the human phenotypes and responsible of perturbation of biological processes (Wild et al., 89 
2005). This novel vision involves different levels of complexity and dimensionality, 90 
providing an integrative overview of the relationship between the internal biological 91 
processes and the environment. Environmental external factors include radiation, infectious 92 
agents, chemical contaminants and environmental pollutants, diet, lifestyle factors (e.g. 93 
tobacco, alcohol), occupation and medical interventions. The exposome includes also the 94 
wider social, economic and psychological dimension for instance the education, the 95 
psychological and mental stress, or climate (Rappaport et al., 2011; Wild et al., 2012, 2013). 96 
As a major difference to the genome, the exposome has an extremely dynamic nature, 97 
entailing complex approaches to accurate characterizations and decipher the interplay of 98 
external factors with the biological processes and human health. The limitations and 99 
challenges have been already identified and discussed elsewhere, proposing approaches more 100 
adapted to the readily accessible technologies and financial budgets, transitioning towards 101 
more integrative settings (Siroux et al., 2016).  102 
The exposome concept has been shaped in parallel to the fast development and 103 
implementation of advanced mass spectrometry (MS) and high resolution mass spectrometry 104 
(HRMS) methodologies to biomonitoring. These approaches, within a “targeted” context, 105 
have allowed the accurate screening and characterization of a wide range of known external 106 
chemical exposures or related metabolites at individual level. Furthermore, the 107 
implementation of HRMS to non-targeted metabolomic approaches has also allowed the 108 
development of novel screening framework to massively identify new environmental 109 
exposures but also internal molecules generated by the intermediary metabolism. The 110 
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chemical spectra of molecules in the organism is believed to account for about 40 nutrients, 111 
2,000 intermediary metabolites, 200,000 peptides and 500000 lipids, whereas about 400,000 112 
chemicals are believed to be part of the exposome (Jones, 2016). The diet is a major pathway 113 
of intake of environmental chemicals, including non-nutritive molecules with potentially 114 
harmful properties like pesticides, environmental pollutants or chemicals often underscored, 115 
like mycotoxins. Currently, more than 300 mycotoxins are known, but scientific and 116 
regulatory attention is focused only on a reduced number of major toxins, in terms of known 117 
occurrence and toxicity.  118 
Given the large potential impact of mycotoxins in terms of human exposure and related 119 
health effects, the ambition of this review is to present this group of chemical compounds and 120 
the high interest to be included in exposome projects. Furthermore, we also attempt to 121 
approach the novel exposome paradigm to more traditional disciplines such as mycotoxin 122 
exposure assessment and mycotoxicology, introducing the new methodological challenges 123 
and translational needs. Hence, we provide an overview of main mycotoxins, major 124 
biomarkers currently developed and biological matrices where these may be found. The 125 
present review is an introductory overview about available methods of detection for 126 
mycotoxins biomarkers, hence we refer readers to more comprehensive reviews if interested 127 
in a deeper insight (Escrivà et al., 2017a; Vidal et al., 2018; Warth et al., 2016). We also 128 
provide an overview of internal exposure levels and potential co-occurrence with 129 
environmental chemicals which highlight the interest of studying the effect of complex 130 
mixtures including mycotoxins. Finally, a general overview about major health effects of 131 
mycotoxins is provided with an example of the potent xenoestrogen zearalenol (ZOL) to 132 
illustrate the high interest of considering fungal toxins in exposome-health studies.  133 
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2. Mycotoxins, chemical contaminants produced by fungi 135 
Mycotoxins are natural toxicants produced by a high number of species of different fungal 136 
genera. The main mycotoxigenic species belong to the genera Fusarium, Claviceps, 137 
Alternaria, Aspergillus and Penicillium (Marin et al., 2013). These species need particular 138 
eco-physiological conditions, like temperature and humidity (water activity), to grow and 139 
synthesize these secondary metabolites which have adverse effects in animal and human 140 
health. The main substrates or crops with capacity to support the growth and accumulation of 141 
these toxins are cereals, nuts, oilseeds, dried fruits, coffee and spices, and their by-products. 142 
The contamination can occur throughout the food chain, both in the field and in the post-143 
harvest stage, depending on the species involved. It must be borne in mind that the same 144 
species can produce more than one mycotoxin, such is the case of Fusarium graminearum, 145 
which produces deoxynivalenol (DON) and zearalenone (ZEA), and also that the same 146 
mycotoxin can be produced by several fungal species, such as ochratoxin A (OTA), which is 147 
produced by Penicillium verrucosum, Aspergillus ochraceus and Aspergillus carbonarius. 148 
Mycotoxins are a structurally diverse group of relatively low molecular mass compounds that 149 
can occur in three possible forms: as free or unmodified, as matrix associated and as modified 150 
forms (Rychlik et al., 2014). The free or unmodified mycotoxins describe the basic 151 
mycotoxin structures formed by a high number of fungi in well-known biosynthetic 152 
pathways. Some examples of these mycotoxins are aflatoxin B1 (AFB1), OTA, patulin 153 
(PAT), DON, fumonisin B1 (FB1), and ZEA. Their chemical structures are very diverse. So, 154 
we find microcyclic lactones like ZEA, small lactones condensed with hetero- or alicycles 155 
like PAT, furan derivatives like aflatoxins (AFs), alicyclic compounds like T-2 toxin, among 156 
others. The matrix associated forms are either complexes with matrix compounds or are 157 
physically dissolved or trapped or are covalently bound to matrix components or a 158 
combination of both effects. Examples of this group are the fumonisins (FBs) bound to 159 
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carbohydrates or proteins. The third group known as modified mycotoxins describes any 160 
modification of the basic chemical structure of the molecules. One of these modifications are 161 
produced by plants through conjugation reactions such as the formation of DON-3-glucoside 162 
(DON-3-Glc). Other conjugation reactions are produced by animals such as the formation of 163 
DON-3-glucuronide (DON-3-GlcA) or by fungi as for example the formation of ZEA-14-164 
sulfate. Among the chemically modified mycotoxins it is possible to distinguish between the 165 
thermally formed and non-thermally formed ones. The first group describes the modifications 166 
produced during the thermal process of foods and feeds with the example of norDON A-C. 167 
The second group is formed by degradation products of the mycotoxins produced under 168 
alkaline conditions like DON-sulfonate.  169 
It is necessary to highlight that the routine analysis of foods and feeds usually determines the 170 
free or parent mycotoxins. In order to identify and quantify the modified forms, validated 171 
methods using highly sensitive equipment like LC-MS/MS is necessary. The industries don’t 172 
usually dispose of these facilities mostly because of economic issues. However, there is a 173 
danger related to the ingestion of these modified mycotoxins, particularly because of their 174 
release into the digestive system and the formation of free forms, which toxic action has been 175 
proved already. Thus, the exposure assessment might not be accurate enough due to the 176 
presence of the modified mycotoxins. Another possible scenario is the exceptional case when 177 
the modified form is more toxic than its parent molecule (e.g. α-ZOL possesses a stronger 178 
oestrogenic potency than ZEA) (Frizzell et al., 2011). 179 
3. Biomarkers of mycotoxin exposure 180 
Biomarkers are measurable biochemical or molecular indicators of either exposure (exposure 181 
biomarker) or biological response (effect biomarker) to a mycotoxin that can be specifically 182 
linked to the proximate cause (Baldwin et al., 2011). More specifically, a biomarker is a 183 
biological measure (parent toxins, protein or DNA adducts, glucuronide conjugates… 184 
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measured in urine or plasma/serum) which is correlated with the quantity of xenobiotic 185 
ingested (Table 1). Validation of a biomarker requires demonstration of assay robustness, 186 
intake versus biomarker level, and stability of stored samples. 187 
Biomarkers have contributed largely to understanding the causative role of AFB1 in human 188 
hepatocellular carcinoma (Kensler et al., 2011). These have included both biomarkers of 189 
exposure, based on urinary aflatoxin M1 (AFM1) and serum AFB1-albumin adduct as 190 
markers of internal dose, and a biomarker of effect, based on urinary AFB1-N7-guanine as a 191 
measure of biological effective dose, since DNA adduct formation is the biochemical 192 
mechanism whereby AFB1 exerts its carcinogenic potency. 193 
Traditional biomonitoring studies of internal exposure through urine or plasma analysis of 194 
target chemicals, metabolites, or reaction products are useful to link exposures to health 195 
outcomes. Biologically persistent chemicals are well-characterized with traditional methods, 196 
whereas short-lived chemicals are effectively measured only if the individual is undergoing 197 
continuous or continual exposures or if the timing of exposures is known. In particular, 198 
urinary excretion mainly represents recent mycotoxin intake, whereas measurements in 199 
plasma/serum are more likely to represent long-term exposure. Very often urine is the matrix 200 
of choice, as it is easily collected, however, its limitation is the differing urine excretion 201 
owing to different fluid intakes. This can be addressed partially by normalization for the 202 
creatinine concentration of a urine sample. In exposure studies it is always recommended to 203 
collect 24-h urine. Stability studies revealed that a wide range of target analytes were stable 204 
for 12 h at 25 °C post-collection (Njumbe Ediage et al., 2012), but to avoid fermentation 205 
problems that can alter any of the components of the sample, conservation at 2-4ºC is 206 
recommended.  207 
 208 
Table 1. Biomarkers of mycotoxin exposure.  209 
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Mycotoxin Biomarker Validated Reference 
Aflatoxin B1  AFM1 in urine 
 
Aflatoxin –N7-guanine adduct in urine 
AFB1 in urine 
AF-Alb in plasma 
Yes (1.2-2.2% of 
ingested AFB1)) 
Yes (0.2% of  
ingested AFB1) 
No 
No specified 
Zhu et al (1987) 
 
Groopman and 
Kensler (1993) 
 
Chapot and Wild, 
1991 
Fumonisin B1  FB1 in urine 
 
HFB1 in urine 
Sa/So in plasma 
Yes (0.08-0.5 of 
ingested FB1) 
No 
Yes 
Van der Westhuizen et 
al. (2011) 
Riley et al. (2012) 
Shephard and Van der 
Westhuizen (1998) 
Deoxynivalenol ‘total DON’ (free DON+DON released by b-
glucuronidase) in urine 
DON in urine 
DOM in urine 
Yes 
 
No 
No 
Turner et al. (2008) 
Ochratoxin A OTA in urine 
OTα in urine 
4-OH OTA in urine 
OTA in plasma 
Yes 
No 
No 
Yes 
Gilbert et al. (2001) 
 
 
Breitholtz et al. (1991) 
Zearalenone ZEA+α-zearalenol+ß-zearalenol in urine 
ZEA-14-GlcA in urine 
ZEA–Glu in urine 
ZEA+α-ZOL+ß-ZOL in plasma 
No 
 
 
Yes 
 
 
 
Prelusky et al. (1989) 
Fumonisin B1 FB2 in urine No  
HT-2 toxin HT-2 toxin in urine No  
Citrinin CIT in urine No  
 DH-CIT in urine 
CIT in plasma 
No 
Yes 
 
Blaszkewicz et al. 
(2013) 
T-2 toxin T-2 toxin in urine No  
 210 
4. Analytical methods to identify mycotoxins biomarkers in urine 211 
Traditional biomonitoring implies developing analysis protocols for each mycotoxin. This 212 
multiplies the volume of sample required, and may be slower and more expensive. Most 213 
mycotoxin exposure assessments in developing countries have focused on the AFs and FB1, 214 
while DON and its modified forms were usually monitored in developed countries. Recently, 215 
an increasing number of studies include biomonitoring of a range of mycotoxins, as a result 216 
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of the advent of the latest generation of high performance LC-MS/MS instruments, however, 217 
they rarely include simultaneously contaminants other than mycotoxins.  218 
Traditional biomonitoring of aflatoxins, has been mainly carried out through AFM1 219 
determination in urine. The method of choice has been usually competitive enzyme-linked 220 
immunosorbent assays (ELISA) kits, or IAC clean-up followed by HPLC-FD detection. 221 
UPLC-MS/MS methods are nowadays preferred. In these cases, urine samples are 222 
centrifuged, diluted in IAC column compatible buffers, cleaned up, evaporated to dryness and 223 
suspended before injection in LC-MS/MS (Jager et al., 2014).  224 
Total urinary DON (free DON plus DON-GlcA) has been usually analysed using 225 
immunoaffinity enrichment and liquid chromatography mass spectrometry (LC-MS) 226 
quantification according to Turner et al. (2008). This method includes a β-glucuronidase 227 
treatment of the centrifuged and pH- adjusted sample, and a subsequent clean-up using a 228 
DON IAC column, with final LC-MS detection (Wallin et al., 2013). Based on samples 229 
analysed with or without enzymatic treatment, it has been observed that free DON is 22% of 230 
the total urinary DON (Srey et al., 2014). Gratz et al. (2013b) developed a similar method of 231 
extraction and clean-up, for urine samples analysis for DON+DON-glucuronide and de-232 
epoxy-deoxynivalenol (DOM-1) using an LC-MS/MS for detection.  233 
Exposure to OTA has been traditionally analysed through urine dilution and clean-up using 234 
IAC prior HPLC-FD quantification of OTA and OTα aglycones (Manique et al., 2008; 235 
Duarte et al., 2015). However, the increasing evidence of the presence of OTA glucuronides 236 
has led to the search for an indirect method, i.e. by comparing levels of OTA aglycone in 237 
urines without and after enzymatic hydrolysis. Considerable increases in OTA levels are 238 
found after enzymatic hydrolysis in some urine samples which provides evidence for the 239 
excretion of OTA-conjugates. Thus enzymatic treatment of urine samples with ß-240 
glucuronidase/arylsulfatase is recommended before samples clean-up with IAC (Muñoz et al., 241 
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2017). Analysis of OTA in enzymatically hydrolized urine samples have demonstrated 242 
considerably higher detection frequencies for OTA than when those samples were directly 243 
analysed by LC-MS/MS, even when OTA-8-β-glucuronide is used as standard, as it shows 244 
very low sensitivity for the metabolite compared to detection of OTA (aglycone) due to a far 245 
lower ionization efficiency (Muñoz et al., 2017). This suggests that OTA conjugates may 246 
escape detection when direct (‘dilute and shoot’) methods are applied for urinary biomarker 247 
analysis (Ali et al., 2018). 248 
Regarding fumonisins, IAC or SPE (Oasis
®
 MAX cartridge, Waters, UK, Gong et al., 2008) 249 
clean-up prior detection by HPLC/MS system is preferred. A highly sensitive method has 250 
been optimized for FB1 and FB2 determination in urine using IAC followed by liquid 251 
chromatography with tandem mass detection (Silva et al., 2009a). Urine has been also 252 
analyzed to identify the surrogates of fumonisin exposure sphinganine (Sa) and sphingosine 253 
(So). The most common method of choice is HPLC–FD after prior derivatization with o-254 
phthaldahyde or naphthalene-2,3-dicarboxaldehyde. An optimized method for urine also 255 
included the isolation of exfoliated cells followed b extraction with ethyl acetate prior 256 
derivatization (Silva et al., 2009b). 257 
Nowadays multibiomarker studies are often undergone by using separation by LC and 258 
detection using triple-quadrupole analyzers coupled via an electrospray ionization (ESI) 259 
interface. However, the degree of sample purification greatly differs from one study to 260 
another. An excellent review on the main analytical issues related to multibiomarkers 261 
determination was published by Warth et al. (2013) and also covered by Vidal et al. (2018).  262 
The first multibiomarker studies in human urine involved separated IAC clean-up for each 263 
toxin of interest and pooling of the purified extracts, or using multi-IAC containing a range of 264 
antibodies against the more relevant mycotoxins, AFM1, OTA, FB1 and FB2 (Ahn et al., 265 
2010). Similarly, using IAC concentration, DON, T-2 toxin, HT-2 toxin, ZEA, OTA, AFB1, 266 
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aflatoxin B2 (AFB2), aflatoxin G1 (AFG1), aflatoxin G2 (AFG2), as well as FB1 and 267 
fumonisin B2 (FB2) were analysed in urine by LC-MS/MS (Rubert et al., 2011). AFM1, 268 
OTA, DON, DOM-1, α-zearalenol/β-zearalenol (α-ZOL/β-ZOL) and FB1 were 269 
simultaneously analysed by LC-MS/MS (plus other SPE after IAC for subsequent sample 270 
preparation, Solfrizzo et al., 2011). Another urinary biomarker study applying an LC-MS/MS 271 
method for the simultaneous determination of DON, OTA, FB1, AFB1, ZEA, T-2 toxin and 272 
citrinin (CIT), as well as their main metabolites in human urine, was developed and validated 273 
(Ediage et al., 2012). The urine samples required solvent extraction and SPE clean-up prior to 274 
analysis by LC-MS/MS. Later, a method developed by Njumbe Ediage et al. (2013) covered 275 
seven mycotoxins and several important conjugation and breakdown products (in total 18 276 
analytes). Sample cleanup was optimized in a progressive procedure where urine samples 277 
were extracted with ethyl acetate/formic acid (99:1, v/v) followed by strong anion exchange 278 
(SAX) SPE cleanup of the acidified aqueous fraction. The combined extracts of the 279 
evaporated organic phase and the SAX eluate were injected into the LC-MS/MS system.  280 
Simultaneously, a multi-biomarker method was developed based on the LC-MS ‘dilute-and-281 
shoot’ approach for the direct detection of the 15 most relevant key mycotoxin metabolites in 282 
human urine without extract purification (Warth et al., 2012). This rapid method utilized an 283 
UHPLC system in tandem with a QTrap 5500 LC-MS/MS system equipped with a Turbo 284 
electrospray ionisation source. The urine sample was simply diluted 1:10 with 285 
acetonitrile/water (10:90) and injected directly into the LC-MS/MS system. The resulting 286 
LODs defined as the signal-to-noise ratio of 3:1 were for each analyte as follows: AFM1 287 
(0.05 μg/L), FB1 (0.5 μg/L), FB2 (0.5 μg/L), OTA (0.05 μg/L), DON (4.0 μg/L), DON-3-288 
GlcA (6.0 μg/L), DOM-1 (10 μg/L), NIV (3.0 μg/L), T-2 toxin (2.0 μg/L), HT-2 toxin (20 289 
μg/L), ZEA (0.4 μg/L), zearalenone-14-glucuronide (ZEA-14-GlcA) (1.0 μg/L), α-ZOL (0.5 290 
μg/L), and β-ZOL (0.5 μg/L). Besides the simplification, the advantage of this workflow is 291 
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the full recovery of the polar conjugates such as glucuronides which are frequently lost 292 
during sample cleanup. The disadvantage of the dilute and shoot approach is the need for the 293 
latest state-of-the art triple-quadrupole mass analyzer to achieve the very low LODs required. 294 
Even when these highly advanced instruments are used, only moderate to high exposure is 295 
detectable, rather than very low background levels. Some other authors have used such 296 
‘dilute and shoot’ approach (Abia et al., 2013), using H2O/ACN/FA as dilution solvent 297 
(Gerding et al., 2014), 1% ammonium acetate (Vidal el al., 2016), or just injection without 298 
dilution (Huybrechts et al., 2015). 299 
Interestingly, Shephard et al. (2013) compared results of urine analysis both with sample 300 
clean-up (single and multi-biomarker) and by a ‘dilute-and-shoot’ multibiomarker method. 301 
Firstly, urinary FB1 was separately determined using a tailor-made single target method as 302 
previously described (Gong et al., 2008) (SPE+LC-MS/MS), secondly, DON, AFM1, FB1, α-303 
ZOL, β-ZOL, ZEA and OTA) were determined as previously described (Solfrizzo et al., 304 
2011) (enzymatic treatment +IAC+SPE+UPLC-MS/MS), finally, urine samples were 305 
analysed for the biomarkers FB1, FB2, AFM1, OTA, DON, DON-3-GlcA, DON-15 306 
glucuronide (DON-15-GlcA), DOM-1, nivalenol (NIV), T-2 toxin, HT-2 toxin, ZEA, ZEA-307 
14-GlcA, and α- and β-ZOL using a ‘dilute-and-shoot’ method without prior β-glucuronidase 308 
treatment as previously described (Warth et al., 2012). The single biomarker method detected 309 
FB1 (87% incidence; mean ± standard deviation 0.342 ± 0.466 ng/mg creatinine) and DON 310 
(100% incidence; mean 20.4 ± 49.4 ng/mg creatinine) after hydrolysis with β-glucuronidase. 311 
The multi-biomarker ‘dilute-and-shoot’ method showed only 51% of FB1 positive samples, 312 
with a maximum value of 2.59 ng/mg, and indicated that DON-15-GlcA was predominantly 313 
present. The multi-biomarker method with β-glucuronidase and immunoaffinity clean-up 314 
determined ZEA (100%; 0.529 ± 1.60 ng/mg creatinine), FB1 (96%; 1.52 ± 2.17 ng/mg 315 
creatinine), α-ZOL (92%; 0.614 ± 1.91 ng/mg creatinine), DON (87%; 11.3 ± 27.1 ng/mg 316 
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creatinine), β-ZOL (75%; 0.702 ± 2.95 ng/mg creatinine) and OTA (98%; 0.041 ± 0.086 317 
ng/mg creatinine). Given its higher LOD, lower incidence was reported for the ‘dilute-and-318 
shoot’ method. On the other hand, the tandem clean-up procedure led to higher mean and 319 
medium values than using SPE clean-up only. Low correlation was observed among the 320 
different methods for FB1 detection. Better correlation was found among DON biomarkers of 321 
exposure (either DON or DON glucuronides). Similarly, Solfrizzo et al. (2103) compared 322 
single biomarker methods for DON and FB1 to multibiomarker methods (dilute and shoot 323 
and tandem IAC), and showed good performance of the three methods for DON, but 324 
questionable for FB1. Between the multibiomarker methods, acceptable performance was 325 
observed for DOM-1, AFM1, ZEA, α-ZOL and β-ZOL, but not for OTA. 326 
Recently, Turner et al. (2017) compared Wallin et al. (2013) single method (SM) to Solfrizzo 327 
et al. (2014) multidetection method (MM) for DON and its modified forms. Both methods 328 
measure free DON plus the β-glucuronidase digest of DON glucuronides. A higher number 329 
of samples were <LOQ by using the MM method probably due to increased LOD as a results 330 
of an increase of matrix effect, that is, higher ion suppression. The higher matrix effect could 331 
be due to the use of an SPE column for urine purification. However, mean DON 332 
concentrations were not statistically different (p > 0.05). Although the analytical approaches 333 
used in the two methods are similar, including immunoaffinity enrichment and LC-MS/MS in 334 
both, several important details are different. First, the pH of urine before enzymatic digestion 335 
was adjusted for the SM method but not the MM method. Second, the enzyme used for urine 336 
digestion was different. Third, the volume of urine analyzed was 1 mL for SM and 6 mL for 337 
MM. Fourth, the enrichment for the mycotoxin included a single-antibody column for the SM 338 
method and several distinct antibodies in the columns plus an SPE-OASIS HLB column for 339 
the MM method. Finally, the SM approach included an internal individual standard spiked at 340 
the outset of extraction, whereas the MM used a matrix-assisted calibration adjusting all 341 
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samples as the mean recovery for the method. As DON-glucuronides can represent a 342 
significant portion of the total DON in urine, it is plausible that these analytical differences 343 
may have affected the efficacy of deconjugation of DON-glucuronides.  344 
In the later years, salting-out assisted liquid/liquid extraction methods and dispersive solid 345 
phase extraction methods have also been developed for multiple mycotoxins and metabolites 346 
analysis in urine (Song et al., 2013), linked to either LC-MS/MS or GC-MS/MS analysis 347 
(Rodríguez-Carrasco et al. 2014). That latter GC-MS/MS method has been successfully 348 
applied to a 24 h pilot diet study revealing that DON was the main mycotoxin in diet and 349 
urine among the 15 Fusarium toxins analyzed (Rodríguez-Carrasco et al., 2015).  350 
Recently, some studies have specifically compared different extraction and micro-extraction 351 
techniques for Fusarium mycotoxins applied to human urine, showing that dispersive liquid–352 
liquid microextraction (DLLME) was the most performant compared to salting-out liquid–353 
liquid extraction (SALLE), miniQuEChERS (quick, easy, cheap, effective, rugged, and safe) 354 
methods (Escrivà et al., 2017b). Conversely, SALLE showed better accuracy and precision 355 
than DLLME in combination with GC-MS/MS for the determination of 10 Fusarium 356 
mycotoxins (Rodríguez-Carrasco et al., 2017). 357 
A comparison of relevant multidetection biomarker methods for analysis of mycotoxins in 358 
urine is presented in Table 2. Warth et al. (2012) reviewed the main limitations encountered 359 
in multibiomarker monitoring. A range of analytical challenges were listed.  360 
a) First is the extremely low analyte concentrations present in biological fluids following 361 
dietary exposure, thus sample preparation is crucial to obtain acceptable LODs. However, the 362 
great chemical diversity of analytes (including polar conjugates such as glucuronides which 363 
are frequently lost during common cleanup approaches such as SPE or IAC procedures) 364 
makes it difficult. IAC cleanup allows for high enrichment, however, no conjugates or other 365 
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biomarkers/analytes of interest can be included in a method, and enzymatic hydrolysis should 366 
be performed to include conjugates. On the other hand, the dilute and shoot approach does 367 
not need further pretreatment; however, to overcome matrix effects and interfering matrix 368 
peaks, eluents, the chromatographic gradient, and the dilution factor need to be carefully 369 
optimized.  370 
b) Second, co-eluting matrix components can negatively influence the accuracy of 371 
quantitative methods through ion suppression or enhancement in the ion source. Ion 372 
suppression can be reduced efficiently by careful optimization of the eluents and gradient. 373 
Using internal standards and matrix-matched calibration is critical. 374 
c) Third, there is a lack of authentic reference standards and certified reference materials. 375 
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Table 2. Comparison of the number of detected biomarkers and LODs of relevant multidetection biomarker methods for analysis of mycotoxins 376 
in urine.  377 
Reference AFM1 FB1+FB2 DON OTA ZEA T-2 HT-
2 
Others Clean-up Total 
Rubert et al. 
2011 
 9 10 0.5 3 2 3 AFB1, AFB2, AFG1, AFG2 IAC 11 
Warth et al. 
2012 
0.05 0.4 4 0.05 0.4 1 12 DON-3-GlcA, DOM1, NIV, ZEA-14-GlcA, α-ZOL, β-
ZOL, DON-15-GlcA 
No 15 
Ediage et al. 
2012 
0.15 2.7 4 0.15 0.6 1 40 AFB1, CIT SPE 7 
Ediage et al. 
2013 
0.01 0.01 0.04 0.03 0.1 0.05 0.42 AFB1, DOM1, CIT, α-ZOL, β-ZOL, ochratoxin α 
(OTα), 4-hydroxyochratoxin A (4-OH-OTA), DON–3-
GlcA, HFB1,  
ZEA–GlcA 
SPE 18 
Abia et al. 
2013 
0.05 1 4 0.05 0.4 2 20 DON-3-GlcA, ZEA-14-GlcA, DON-15-GlcA, DOM-1, 
NIV, α-ZOL β-ZOL 
No 15 
Gerding et al. 
2014 
0.025 0.25 0.5 0.1 0.025 0.25 2 Zearalanone (ZAN), α-ZOL, β-ZOL, AFB1, AFB2, 
AFG1, AFG2, dihydrocitrinone (DH-CIT),  enniatin B, 
OTα, DON-3-GlcA, ZEA-14-GlcA, ZAN-14-GlcA, α-
ZOL-14-GlcA, β-ZOL-14-GlcA, and HT-2-4-GlcA 
No 24 
Rodriguez- 
Carrasco et al. 
2014 
  0.12  3 0.5 1 DOM1, 3-acetyl-DON, fusarenone-X (FusX), 
diacetoxyscirpenol (DAS), NIV, neosolaniol , ZAN, α-
zearalanol, ß-zearalanol, α-ZOL, ß-ZOL 
Dispersive 
SPE 
15 
Huybrechts et 
al. 
0.002 0.1 0.2 0.001 0.02 0.01 0.2 AFB1, AFB2, AFG1, AFG2, CIT, OH-CIT, DAS , 
DON-3-GlcA, DON-15-GlcA, 3-ADON, 3-ADON-15-
No, 
except for 
32 
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2015 GlcA, 15-ADON, 15-ADON-3-GlcA, DOM1, DOM1-
GlcA, FusX, OTA, ZEA-14-GlcA, -ZOL, -ZOL-
GlcA, -ZOL-14-GlcA, -ZOL, -ZOL-14-GlcA   
OTA, 
CIT, 
AFM1 
(IAC) 
Vidal et al. 
2016 
  0.5 0.003    OTα DON-3-glucoside, 3-ADON, 
DOM-1  
DON-3-GlcA 
No 8 
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5. Analytical methods to identify mycotoxins biomarkers in blood 378 
Biomonitoring of aflatoxins in blood was initially carried out by directly analyzing this group 379 
of toxins (including AFB1, AFB2, AFG1, AFG2, AFM1, aflatoxin B2a (AFB2a), aflatoxin 380 
BG2a (AFG2a), aflatoxin P (AFP) and aflatoxicol) in serum samples by 2D-TLC, previous 381 
extraction with dichloromethane and purification on a silica gel column (Hatem et al., 2005), 382 
or by RP-HPLC with fluorescence detection, previous extraction of samples with chloroform 383 
and hexane (Lopez et al., 2002).  384 
However, nowadays the determination of the AFB1-albumin (AFB1-Ab) adduct in serum 385 
(adduct formed with the lysine amino acid of albumin) is more frequently used, as it has been 386 
demonstrated that the concentration of this adduct in serum is strongly correlated with 387 
aflatoxin intake, which makes it a very useful exposure biomarker (Wild et al., 1992). 388 
Adducts could be formed not only with AFB1, but also with the other main aflatoxin (AFB2, 389 
AFG1 and AFG2). Besides, the AFB1-Ab adducts presents a half-life in the organism of 390 
around 2-3 months, what makes this compound a good biomarker to reflect exposures over 391 
long periods of time, in contrast to what happens with the AFB1-N7-guanine adduct 392 
biomarker in urine, that better reflects day-to-day variations in aflatoxin intake. Moreover, 393 
AFB1-Ab adducts are stable in serum samples stored at -80 °C for over 25 years, allowing for 394 
re-analysis of archived samples years later (Scholl and Groopman, 2008). 395 
For the analysis of the AFB1-Ab adducts in serum, ELISA seems to be the routine analysis 396 
method; samples are previously digested with pronase, extracted and purified and measured 397 
using a competitive ELISA (Chapot and Wild, 1991; Turner et al., 2007, 2008; Gong et al., 398 
2012; Piekkola et al., 2012; Shirima et al., 2013, 2015; Asiki et al, 2014; Chen et al., 2018). 399 
However, other techniques as RIA (Jiang et al., 2005; Tang et al., 2009), HPLC-FD (Mizrak 400 
et al., 2009; Shuaib et al., 2012) and HPLC with isotope dilution mass spectrometry (IDMS) 401 
(McCoy et al., 2005, 2008) have been also used. 402 
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In relation to FBs, direct detection of FB1 in blood samples has not been considered an 403 
appropriate biomarker, due to its rapid elimination and low oral bioavailability. Taking into 404 
account the effect of FBs on the metabolism of sphingolipids (inhibition of the ceramide 405 
synthase enzyme and increase of intracellular Sa concentration), the ratio between Sa and So 406 
(or between Sa-1-phosphate and So-1-phosphate) in plasma has been considered an indirect 407 
indicator of human FBs exposition, and therefore it has been frequently used. However, this 408 
ratio has been considered useful in studies with animals, but in human exposure studies, when 409 
the level of food contamination is relatively low, wide ranges of Sa:So ratios and bad 410 
correlation coefficients have been observed when linear regression was fitted, which suggests 411 
that this ratio present low sensitivity and imprecision in humans (Cano-Sancho et al., 2010). 412 
The analytical method used to determinate these metabolites frequently included plasma 413 
deproteinization, liquid-liquid extraction, hydrolysis and purification, and HPLC-FD analysis 414 
prior derivatisation with o-phthaldialdehyde (Riley, 1994; Shephard and Van der Westhuizen, 415 
1998; Castegnaro et al., 1998), although use of blood spots, LC-MS determination has also 416 
been used (Riley et al., 2015).  417 
Direct OTA detection in human plasma has been widely used, as OTA binds rapidly and with 418 
high affinity to plasma proteins, constituting therefore a good biomarker of exposure 419 
(Coronel et al., 2010; Lino et al., 2008). The method of choice for detection is the HPLC-FD, 420 
and usual methods of analysis comprise liquid-liquid extraction of plasma samples, for 421 
example with acidified ethyl acetate or other solvents, and analysis by HPLC-FD with 422 
postcolumn confirmation through the formation of OTA-methyl ester (Palli et al., 1999), 423 
purification of acidified plasma samples with a C18 Sep-Pak cartridge and analysis by 424 
HPLC-FD with confirmation through the formation of OTα after carboxypeptidase treatment 425 
of samples (Creppy et al., 2005), and other similar methods (Ali et al., 2018), many of them 426 
using immunoaffinity columns (Ghali et al., 2008). Other methods used included detection of 427 
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ochratoxins in plasma by ELISA (Ueno et al., 1998) or LC/MS/MS (Lau et al., 2000; Medina 428 
et al., 2010; Cramer et al., 2015). 429 
Regarding DON, to date, DON, DON-GlcA and DOM-1 in urine are the preferred 430 
biomarkers for the study of DON exposure. However, several attempts have been made to 431 
find DON biomarkers linked to blood samples. Thus, from studies with rodents, Kim et al. 432 
(2008) have proposed the use of plasma haptoglobin, measured using SELDI-TOF/MS as a 433 
diagnostic biomarker for DON intoxication when this is combined with examining the serum 434 
immunoglobulins. These findings have led to a patent application in Korea (patent reference 435 
number KR100809952B1) protecting a diagnostic kit for the evaluation of toxicity and 436 
exposure for DON using haptoglobin-specific protein. However, different results have been 437 
found in experiments with lactating dairy cows (Kinoshita et al., 2015), and, to date, no data 438 
are available in the case of human blood.  439 
With respect to other mycotoxins few studies have been conducted to assess the presence of 440 
other fungal toxins in human blood. Thus, in the case of ZEA, the presence of this metabolite 441 
or its congeners (α-ZOL, ß-ZOL) has been studied in plasma of patients with breast and 442 
cervical cancer by HPLC and GC (Pillay et al., 2002), whereas Massart et al. (2008) studied 443 
the presence of ZEA and derivatives in the serum of healthy girls and affected by central 444 
precocious puberty, performing an enzymatic treatment of samples with glucuronidase, 445 
followed by purification through a immunoaffinity column and analysis by HPLC-FD. On the 446 
other hand, Fleck et al. (2016) have studied the presence of total ZEA (ZEA plus conjugated 447 
metabolites) and total α-ZOL in serum of pregnant women by UPLC-MS/MS and 448 
electrospray ionization (ESI). 449 
Finally, for CIT, studies on human plasma have been developed by means of an acetonitrile 450 
protein precipitation followed by centrifugation and analysis by HPLC-FD and LC-MS/MS 451 
(Blaszkewicz et al., 2013; Ali et al., 2018). 452 
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Regarding plasma or serum, few studies have carried out on multi-detection analysis of 453 
mycotoxins including multiple mycotoxin biomarkers of different mycotoxins groups in one 454 
sample at the same time, mainly due to the high matrix complexity. Thus, in plasma most 455 
methods have only focused on the analysis of structurally-related mycotoxins belonging to a 456 
single family. 457 
Osteresch et al. (2017) have developed a rapid multi-mycotoxin method, using dried whole 458 
blood spots and dried serum spots, which allows for the simultaneous detection and 459 
quantification of a great variety of fungal toxins by HPLC-MS/MS in less than 10 minutes. 460 
This method is able to detect till 27 mycotoxins, of the following groups (data of LOD in 461 
ng/mL is given): aflatoxins (AFB1: 0.012; AFB2: 0.013; AFG1: 0.021; AFG2:0.037; AFM1: 462 
0.017), Alternaria toxins (alternariol: 0.142; alternariol monomethyl ether: 0.146; altenuene: 463 
0.147), enniatins (A: 0.0016,: A1: 0.0055; B: 0.0012; B1: 0.0044), ochratoxins (OTA/2’R-464 
ochratoxin A: 0.012; OTα: 0.014; 10-hydroxyochratoxin A: 0.015), T-2/HT-2 group (T-2 465 
toxin: 0.227; HT-2 toxin: 1.344; HT-2-4-glucuronide: 0.709), ZEA (0.294) and ZAN (0.273), 466 
CIT (0.066) and DH-CIT (0.268), FB1 (0.521) and beauvericin (0.014), with average 467 
recoveries above 90% in most of the cases. 468 
De Santis et al. (2017) have described a method for the analysis of 8 mycotoxins (AFB1, 469 
AFM1, FB1, OTA, ZEA, DON, DOM-1, and gliotoxin –GLIO–) that combine pronase 470 
treatment of serum samples followed by QuEChERS purification and LC-MS detection. 471 
Limits of quantification were low for AFB1 (0.01 ng/mL), AFM1 (0.22 ng/mL) and OTA 472 
(0.16 ng/mL), but in other mycotoxins were above 5 ng/mL (DON, DOM-1) or 11 ng/mL 473 
(GLIO). The absolute recoveries of the method were not too high, since, with the exception 474 
of AFB1 (82%), all the toxins had recoveries below 63%. 475 
Cao et al. (2018) have also described a method for the quantitative determination of 476 
mycotoxins in human plasma, as well as in other biological matrices (like urine) and animal 477 
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derived foods, by HPLC-MS/MS. This method is valid for the determination of aflatoxins in 478 
human plasma (data of LOD in ng/mL is given) (AFB1: 0.07; AFB2: 0.05; AFG1: 0.13; 479 
AFG2:0.15; AFM1: 0.16), as well as of FBs (FB1: 0.41; FB2: 0.39), sterigmatocystin (0.05), 480 
PAT (0.35), CIT (0.18) and OTA (0.15). Sample preparation consisted in a treatment of 481 
plasma with ß-glucuronidase, deproteinization with acetonitrile/acetic acid and evaporation. 482 
Recently, Slobodchikova and Vuckovic (2018) have described a LC-MS method for the 483 
simultaneous detection of 17 mycotoxins in human plasma. Studied mycotoxins are NIV, 484 
DON, 3-ADON, 15-ADON, T-2 toxin, HT-2 toxin, AFB1, AFB2, AFG1, AFG2, ZEA, ZAN, 485 
α-ZOL, ß-ZOL, α-zeranol, ß-zeranol and fusarenon X (FusX). The method avoids the use of 486 
immunoaffinity columns thanks to a three-step liquid-liquid extraction procedure with ethyl 487 
acetate. LOQ of all mycotoxins ranged from 0.1 to 0.5 ng/mL, except NIV (3 ng/mL). This 488 
method is not suitable for OTA, FB1 and FB2 489 
Covering a smaller number of mycotoxins, Serrano et al. (2015) have developed a method for 490 
the simultaneous determination of enniatins (A, A1, B and B1) and beauvericin in human 491 
plasma by HPLC-MS/MS. The method consisted in the deproteinization of samples with 492 
MeOH/H2O (40/60, v/v) followed by solid phase extraction, using in-house prepared 493 
Carbograph-4 SPE column, and detection by HPLC-tandem mass spectrometry with an 494 
electrospray ion source. Experimental LOD obtained were 10 ng/L for enniatins A1 and B, 20 495 
ng/L for enniatin B1 and beauvericin, and 40 ng/L for enniatin A, and recoveries ranged 496 
between 90 to 120%. 497 
6. Biomarkers of mycotoxins in breast milk 498 
The use of breast milk in biomonitoring studies and epidemiological birth cohort studies is 499 
gaining interest due to the large chemical information contained and the easy collection 500 
methods resulting in a non-invasive and valuable biological matrix. By default, breastfeeding 501 
is considered the “gold-standard” diet for infants, however it has been questioned the 502 
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potential health risk associated when mothers are subjected to contaminated diets. The tight 503 
relationship between blood and breast milk compartments results in high and rapid 504 
transference of lipophilic chemicals, however the transference of mycotoxins from blood to 505 
human breast milk and overall occurrence, has been scarcely explored (Reviewed by Warth et 506 
al., 2016). The high interest of studying the concentrations of harmful chemicals in breast 507 
milk is justified not only by the exploration of mother’s internal exposure levels but also the 508 
external exposure of infants during critical windows of development. The vulnerability is 509 
reflected by the low maximum tolerable levels established in baby foods and infant formulas 510 
by regulatory agencies, which enforce those products to rigorous inspections. Surprisingly, 511 
little effort has been addressed to evaluate the levels of mycotoxins in breast milk and risk-512 
benefits derived from breastfeeding. The preparation of samples commonly involves 513 
immunoaffinity columns, liquid-liquid or solid-phase extraction, and the major methods of 514 
detection are based on ELISA kits, liquid HPLC-FD and LC-MS/MS. Maternal determinants 515 
of AFM1 in breast milk determined by ELISA included the season of collection, education 516 
level, lactation stage or consumption of rice and chocolate (Bogalho et al., 2018). The 517 
implementation of multi-mycotoxin detection methods in breast-milk remains as a major 518 
challenge nowadays, yet few studies have published screening exploratory studies (Andrade 519 
et al., 2013; Rubert et al., 2014). As recently summarized by Warth et al. (2016), most studies 520 
have evaluated the occurrence of AFM1 (Brazil, Cameroon, Columbia, Egypt, Iran, Italy, 521 
Jordan, Kuwait, Nigeria, Serbia, Sudan, Tanzania and Turkey) or OTA and related 522 
metabolites (Chile, Egypt, German, Iran, Italy, Poland, Slovakia, Turkey, Brazil and Chile). 523 
Conversely, few studies have explored the levels of AFB1 (Turkey and Egypt), FB1 524 
(Tanzania) or ZEA (Italy). Most studies exploring AFM1 showed percentages of positive 525 
samples exceeding the 25% of analysed samples and mean concentrations of positive samples 526 
ranged from 0.56 and 44000 ng/L (Warth et al., 2016). These values appear specially 527 
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concerning if we consider the maximum concentration levels set up by the European 528 
Commission in infant formula was 0.025 ng/mL (European Commission, 2006).  529 
7. Internal exposure of general population to mycotoxins.  530 
In the last few years an increasing number of studies have been published on assessment of 531 
exposure to mycotoxins in different countries using biomarkers. Most single biomarker 532 
studies dealt with exposure to AFB1 through AFM1 determination in urine. Moderate to high 533 
frequencies were reported all over the world, depending on the LOD of the methods used. In 534 
general, mean and median values under 0.1 ng/mL were detected in different countries in 535 
Asia, America and Europe. Higher absolute concentrations were reported in some countries 536 
in Africa (up to 3.7 ng/mL) (Smith et al., 2017).  Using direct detection of AFB1 in blood, 537 
values from different studies ranged from 0.08 to 7.4 ng/mL, whereas when the AFB1-538 
albumin biomarker was used the values ranged from not detected to values as high as 268 539 
pg/mg. A good review about these data can be found in Waseem et al. (2014). 540 
Secondly, DON exposure through urine analysis was assessed mainly in European countries, 541 
where frequencies in the range 90-100% were usually reported in urine samples, with 12% 542 
found as free DON and 88% as DON glucuronides (Wells et al., 2016). Mean levels of DON 543 
were around 10 ng/mL, while when total DON was assessed higher levels were reported, and 544 
higher total levels could be over 400 ng/mL (Wells et al., 2016). Several studies confirmed 545 
that a significant percentage of the populations were exposed to levels over the TDI. Lower 546 
frequencies of occurrence were observed in other countries like Bangladesh or Tanzania, 547 
where the different dietary habits may be determinant. 548 
Finally, those studies devoted to OTA in Europe reported widely variable frequencies, but 549 
low general levels (mean under 0.3 ng/mL) (Ali et al., 2018; Wallin et al., 2013; Duarte el al., 550 
2015). In blood, OTA has been detected in a great number of studies, with OTA occurrence 551 
frequently over 74% and usually over 90% (Coronel et al., 2010; Waseem et al., 2014), and 552 
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with a global estimation (derived from a big number of published studies) of minimum, 553 
maximum and mean levels of 0.15, 9.15 and 0.45 ng OTA/mL plasma, respectively (Coronel 554 
et al, 2010). 555 
Differences in nutritional habits and quality of consumed foodstuffs are likely the reason for 556 
interregional variations in mycotoxin excretion.  557 
Regarding multibiomarker studies, as shown in Table 3, DON, OTA and AF were the more 558 
often searched and detected mycotoxins, and they co-occurred in most samples. The 559 
frequencies for DON and OTA were high, but low for AFM1 (in contrast to what observed 560 
using single analysis). Only one study reported frequent exposure to ZEA (Solfrizzo et al., 561 
2014). The detected levels, in general, paralleled those observed in the single biomarker 562 
studies, with high concentration for total DON, followed by FB1, DH-CIT, OTA, total ZEA 563 
and AFM1. Nevertheless, differences in analytical methodology and diversity in available 564 
biomarkers limit comparison of the results. 565 
In contrast to what happens with urine, to date there are not many multimycotoxin studies 566 
conducted in blood (Table 3).  567 
De Santis et al. (2017) studied 8 different mycotoxins (AFB1, AFM1, ZEA, OTA, FB1, 568 
DON, DOM-1, GLIO) in the serum of autistic patients and two control groups (one of 569 
siblings and the other of non-parental persons). In all groups OTA was the prevalent 570 
mycotoxin, with mean prevalence of 82.9% of samples in the whole group and 85.1% in the 571 
autistic. For the rest of mycotoxins, all mean values found were below LOQ. Few samples 572 
showed co-occurrence of different mycotoxins (AFB1, AFM1 and OTA in 4% samples, and 573 
AFB1, AFM1, OTA and GLIO in 2% samples). 574 
The most complete is a recent study by Cao et al. (2018), developed in the People’s Republic 575 
of China, in which the plasma of 30 healthy individuals has been analyzed and compared to 576 
that of 30 hepatocellular carcinoma patients. Eleven mycotoxins were simultaneously 577 
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analyzed by HPLC-MS/MS. In the plasma of control patients the most frequently mycotoxin 578 
found was AFB2 (1.37-3.89 ng/mL; 16.6% samples), followed by AFB1 and 579 
sterigmatocystin (13.3%), and AFG1, AFG2, AFM1, FB1 and FB2 (3.3%). No PAT nor CIT 580 
were found in these samples. Higher percentage of positive samples was found in plasma 581 
from hepatocellular carcinoma patients, with sterigmatocystin being the more frequently 582 
found mycotoxin (1.06-3.23 ng/mL; 40%), followed by AFB1 (33.3%) and AFB2 (23.3%). 583 
However, in plasma AFG1, AFG2, AFM1, OTA and CIT were detected just at the LOD of 584 
the method in both kinds of samples, authors not excluding that these results could be false 585 
positives.586 
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Table 3. Mycotoxins detected in urine and blood/plasma samples through multidetection methods (%positives/mean (ng/mL))  587 
Urine biomarkers 
Reference 
Country (Samples) 
DON DON-GlcA OTA AFM1 ZEA  -ZOL β-ZOL FB1-FB2 DH-CIT  
Gerding et al. 2015 
Haiti (142) 
17/3.2 21/17.0 33/0.109 8/0.06  3/1.46  3/0.44 14/0.49  
Germany (50) 16/2.0 54/11.2 30/0.040 n.d.  n.d.  n.d. 28/0.12  
Bangladesh (95) n.d. n.d. 76/0.203 8/0.06  n.d.  1/- 75/2.75  
Solfrizzo et al. 2014 
Italy (52) 
96/11.89  100/0.144 6/0.068 100/0.057 100/0.077 98/0.090 56/0.055   
Wallin et al. 2015 
Sweden (252) 
63/5.38  51/0.90   21/0.13 18/0.10 6/0.07   
Abia et al. 2013 
Cameroon (175) 
6/- 41/5.49 16/0.09 9/0.05 2/0.22 1/-  3/0.63   
Gerding et al. 2014 
Germany (101) 
29/3.38 82/12.21       12/-  
Heyndrickx et al. 
2015 
Belgium (239) 
37/3.9 100/61.3 35/0.278   0.4/0.005   12/0.752  
Ezekiel et al. 2014 
Nigeria (120) 
0.8/2 5/3.5 28/0.2 14/0.3 0.8/0.3   13/4.6   
Warth et al. 2014 
Thailand (60) 
 12/12.4 2/- 5/0.33       
Blood/serum biomarkers 
Reference 
Country (Samples) 
DON DOM-1 OTA AFB1-
AFB2 
AFG1-AFG2 AFM1 CIT ST PAT ZEA FB1-FB2 GLIO  
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De Santis et al. 
2017 
Italy 
Control group 1 
(35) 
Control group 2 
(18) 
 
 
 
22.9/0.5 
12.5/0.8 
 
 
 
17.1/0.3 
6.3/0.1 
 
 
 
77.1/0.27 
75/0.28 
 
 
 
25.7/0.002 
(AFB1) 
6.3/0.00 
(AFB1) 
  
 
 
45.7/0.07 
31.3/0.06 
    
 
 
8.6/0.1 
0/0 
 
 
 
2.9/0.04 
0/0 
 
 
 
14.3/06 
18.8/10.3 
 
Cao et al. 2018 
PR of China (30) 
  traces 13/0.95-1.78  
(AFB1) 
16.6/1.37-
3.89 (AFB2) 
3.3/0.61 
(AFG1)- 
0.43(AFG2) 
3.3/0.57 traces 13/0.88-
2.05 
n.d.  3.3/1.92 
(FB1) 
3.3/2.03 
(FB2) 
  
 588 
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 589 
Table 4 summarizes the calculated daily intakes from the mycotoxin concentration in urine in 590 
some multibiomarker studies. In summary, between 6 and 29% of the populations considered 591 
were exposed to DON at levels over the TDI, suggesting a medium but worrying risk for the 592 
population, and at the same time they could be exposed to OTA or AFB1 levels of concern. 593 
Since AFB1 is a potent mutagenic carcinogen, no TDI values are established. The presence of 594 
AFM1 in urine samples is of concern. The TDI of 2 μg/kg b.w. for FB1 was never exceeded 595 
by healthy population.  596 
  597 
Table 4. Calculated daily intake from some exposure studies (mean/max/% exceeding TDI). 598 
 DON OTA AFB1 FB1 
Reference (n) TDI  
1 µg/kg bw 
TDI  
0.017 µg/kg bw 
- TDI  
2 µg/kg bw 
Gerding et al. 
2015 
Haiti (142) 
0.27/4.38/6  0.03/0.23/- 0.05/1.74/0 
Germany (50) 0.3/2.15/6  - - 
Bangladesh (95) -  0.03/0.195/- 0.03/1.362/0 
Solfrizzo et al. 
2014 
Italy (52) 
0.59/3.37/6 0.139/2.07/94 0.668/0.142/- 0.274/1.759/0 
Abia et al. 2013 
Cameroon (175) 
HIV sub-
populations 
0.21/2.59/- 0.004/0.094/- 0.0425/1.15/- 5.25/123.3/- 
Gerding et al. 
2014 
Germany (101) 
0.52/5.67/12    
Heyndrickx et al. 
2015 
Belgium (239) 
1.24/10.08/29 0.001/0.021/1   
 599 
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Multi-detection methods have allowed assessing the levels of co-exposure to different 600 
mycotoxins by an individual through urine analysis. Consequently, it has been confirmed that 601 
co-occurrence of two toxins in a urine sample is usually common (more than single 602 
contamination), however results depend highly on the analysed toxins, if only parent 603 
mycotoxins were analysed, 1-2 toxins are usually reported, while if both parent and modified 604 
mycotoxins are analysed 2 to 4 toxins are usually found in a sample. Moreover, lower LOD 605 
of the methods led to higher reported co-occurrence. For example, Gerding et al. (2015) 606 
reported that between 16-54% samples contained two detectable toxins, between 6 and 20 607 
samples contained 3 toxins and 1-2% contained 4 toxins. DH-CIT and OTA usually co-608 
occurred as well as DON and DON-GlcA, and also 3 of them. Fusarium toxins and OTA 609 
have been also shown to occur (Wallin et al., 2015), for example, DON, ZEA, OTA and 610 
DON, ZEA, FB1, OTA, co-occurred in 38 and 52% of urine analysed samples (Solfrizzo et 611 
al., 2014). Studies on exposure in Cameroon reported 4% co-exposure to AFM1 and DON, 612 
3% to OTA and DON and 5% to DON and NIV (Abia et al., 2013). 613 
8. Co-exposure of mycotoxins with other environmental chemicals 614 
A major research gap is the potential concurrent exposure of mycotoxins with other 615 
environmental chemicals that may exhibit some interactive activity and/or exert some 616 
biological function converging in the same molecular pathways. As far as we know, there are 617 
not biomonitoring studies exploring the simultaneous presence of a panel of environmental 618 
chemicals including some type mycotoxin. However, the estimates relying on dietary 619 
exposure modelling suggest that multiple patterns of co-exposure are likely within general 620 
population. The research on mixture identification from the second French Total Diet Study 621 
revealed the extended exposure to mycotoxins in complex mixtures with other environmental 622 
chemicals in most of French diet clusters. For instance, a first cluster containing 18% of the 623 
whole population, was expected to have a significantly higher exposure to mycotoxins (HT-2 624 
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toxin, DON, ZEA and NIV), polycyclic aromatic hydrocarbons (PAHs) (pyrene and 625 
phenanthrene) and bisphenol A, than the whole population. The estrogenic ZEA was also 626 
identified in another cluster with many PAHs, acrylamide, trace elements, pesticides and the 627 
sum of eight polybrominated diphenyl ethers in a cluster representing the 21% of the 628 
population with dietary habits related to junk food and identified as “Snacking” (Traore et al., 629 
2016). Using a similar approach based on the identification of consumption systems 630 
integrated with exposure data, different clusters of pregnant mothers from the two large 631 
French cohorts “Étude Longitudinale Française depuis l’Enfance” (ELFE) and “L’étude des 632 
déterminants pré et post natals du développement et de la santé des enfants” (EDEN), were 633 
identified to be more exposed to mycotoxins simultaneously with other environmental 634 
chemicals. The model was comprehensive including 210 chemicals of which 18 were major 635 
mycotoxins or parent compounds. The “Myco-Pest-PAH” mixture identified from EDEN 636 
before pregnancy was also found in EDEN during pregnancy. It contained eight mycotoxins 637 
(α-ZAL, α-ZOL, diacetoxyscirpenol (DAS), DON-3-GlcA, FusX, OTB, OTA and HT-2 638 
toxin), three pesticides (chlorpyrifos-methyl, cyproconazole and pirimiphosmethyl) and four 639 
PAHs (benzo[g,h,i]perylene, benzo[e]pyrene, cyclopenta(c,d)pyrene and indeno[1,2,3-640 
cd]pyrene). In EDEN before pregnancy, these substances were associated with nine other 641 
pesticides (pyriproxyfen, tetradifon, sulphur, chlorothalonil, diethofencarb, flutriafol, 642 
iprodione, ethion and bifenthrin) and an additive (sulphites). In EDEN during pregnancy, 643 
these substances were associated with three other mycotoxins (DON, DON-15-GlcA and 644 
ZEA), a PAH (pyrene), two phytoestrogens (daidzein and genistein), a trace element 645 
(gallium), a pesticide (sulphur) and two perfluoroalkyl acids, perfluorobutane sulfonate and 646 
perfluorohexanesulfonic acid (Traore et al., 2018). Despite the uncertainties related to the 647 
dietary modelling methodologies, these results provide strong evidence concerning the 648 
potential co-exposure of highly bioactive mycotoxins like -ZEA with many environmental 649 
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chemicals during highly sensitive developmental windows. These modelling studies provides 650 
also light on the potential weight of mycotoxins in the human chemical exposome, as 651 
suspected by the extensive occurrence of mycotoxins in diets.  652 
These profiles extracted from a European diet only represent a region where strict mycotoxin 653 
control regulation is enforced, underscoring the weight of mycotoxins in the chemical 654 
exposome of population in developing countries. The “traditional” fungal contamination of 655 
cereals with the mycoestrogen ZEA, has been identified as a major public health challenge 656 
co-existing with emerging chemical exposures resulting of unstructured industrial 657 
development resulting on high exposures to lead, air pollution, pesticides or e-waste by-658 
products (Bornman et al., 2017).  659 
 660 
We have failed to find in the literature examples of targeted approaches that use liquid or gas 661 
MS methods for the simultaneous detection of mycotoxins and environmental contaminants 662 
in biological specimens. An inspiring example is the method developed by LC-MS with 663 
previous SPE for the simultaneous determination of mycotoxins (AFB1, OTA and PAT) and 664 
bisphenol A in food matrices that could be adapted and applied for urine samples (Song et al., 665 
2013). Novel analytical workflows based on HRMS untargeted metabolomic approaches may 666 
become efficient solutions to overcome existing analytical challenges for the screening of 667 
large panel of chemicals including well-known chemicals. A proof-of-concept study has 668 
recently presented a novel workflow for analysis of blood and urine based on HPLC coupled 669 
to Bruker Impact II quadrupole time-of-flight (Q-TOF) mass spectrometer with a previous 670 
simple sample preparation (Warth et al., 2017). The panel of detected features are further 671 
explored using machine-learning algorithms combined to the XCMS/METLIN platform to 672 
elucidate the pathways related to the annotated signature. Through the pilot study the authors 673 
P O
 S 
T P
 R
 I N
 T
36 
 
demonstrated to efficiently identify low concentrations of common xenoestrogens such as 674 
genistein, ZEA and triclosan at in commercial biological matrices. 675 
9. Mycotoxins and human health effects 676 
The disease caused by mycotoxins is called mycotoxicosis. Mycotoxins can be a threat to 677 
both animal and human health. Oral ingestion of contaminated food is the most frequently 678 
exposure way, however dermal contact and inhalation can also occur (Marin et al., 2013). 679 
Their toxic effect depends on the toxicity of each mycotoxin, the extent of exposure, age and 680 
nutritional status of the individual and possible synergistic effects with other chemicals that 681 
the individual is exposed. Infants is considered the most vulnerable population group due to 682 
the relative inefficiency of detoxification pathways and high relationship of between internal 683 
doses per body weight. 684 
There are more than 300 known mycotoxins which are suspected of widely differing modes 685 
of action, however formal toxicological evaluation and comprehensive risk assessment have 686 
been conducted only for environ 10 of most known or major mycotoxins. Consequently, very 687 
little is known about the potential toxicological and biological effects of secondary 688 
mycotoxins, metabolites or emerging mycotoxins. 689 
To date, most toxicological evaluation is based on experimental studies, including in vitro 690 
and in vivo studies, conversely the body of evidence from human studies is limited to few 691 
epidemiological studies or case studies conducted shortly after human mycotoxicosis 692 
outbreaks. An overview of major health effects of mycotoxins at different toxicological levels 693 
is summarized at Table 5, nonetheless readers may find more detailed reviews published in 694 
the literature (Bui-Klimke et al., 2015; EFSA 2017; Kensler et al., 2011; Marin et al., 2013; 695 
Peraica et al., 1999; Puel et al., 2010). 696 
Table 5. Overview of major health effects of mycotoxins at different toxicological levels.  697 
Mycotoxin 
group 
Interaction 
Nuclear Receptor 
Cellular 
responses 
Health 
effects 
Animals 
Health 
effects 
Humans 
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AFB1  
AFM1 
Pregnane X 
receptor  
Constitutive 
androstane receptor 
Aryl hydrocarbon 
receptor  
Vitamin D receptor 
Formation of DNA 
adducts 
Lipid peroxidation 
Bioactivation by 
cytochromes P450 
Conjugation to GS-
transferases 
Hepatotoxicity 
Genotoxicity 
Carcinogenicity 
Immunomodulation 
Cancer 
Impaired child growth 
FB1 - Inhibition of ceramide 
synthesis 
Adverse effect on the 
sphinganine/sphingosine 
ratio 
Adverse effects on the cell 
cycle. 
Central nervous system 
damage 
Hepatotoxicity 
Genotoxicity 
Immunomodulation 
Oesophageal cancer 
Liver cancer 
Neural tube defects 
Impaired child growth 
OTA - Effect on protein 
synthesis. 
Inhibition of ATP 
production 
Detoxification by 
peptidases 
Nephrotoxicity 
Genotoxicity 
Immunomodulation 
Nephritic syndrome 
BEN 
 
PAT Ø Indirect enzyme inhibition 
In vitro mutagenesis 
Neurotoxicity 
Immunotoxicty 
Disruption of barrier 
function 
 
- 
DON 
NIV 
T-2 toxin 
HT-2 toxin 
Peroxisome 
proliferator-
activated receptor 
Liver X receptor 
Retinol X receptor 
G-protein coupled 
receptor 
Apoptosis  
Oxidative stress 
Inhibition protein 
synthesis 
 
Hematotoxicity 
Immunomodulation 
Skin toxicity 
Anorexia and vomiting 
Reduced weight gain 
Disruption of barrier 
function 
 
Hormone-dependent 
cancer 
Acute mycotoxicosis 
ZEA 
ZOL 
Estrogen Receptor-
and - 
Binding to oestrogen 
receptors 
Bioactivation by 
reductases 
Conjugation to 
glucuronyltransferases 
Reproductive adverse 
effects 
Thelarche 
Precocious puberty 
Breast cancer  
 698 
Among the toxicological initiating events, the interaction of most mycotoxins with nuclear 699 
receptors has been scarcely explored (reviewed by Dall’Asta, 2016). The exception is the 700 
case of ZEA and ZOL whose potent actions to activate the oestrogen receptor pathway and 701 
trigger endocrine perturbations merits an entire section presented hereafter. AFB1 has been 702 
found to modify the expression of nuclear receptors such as pregnane X receptor (PXR), 703 
constitutive androstane receptor (CAR), and aryl hydrocarbon receptor (AhR) at 704 
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transcriptional level, and also causing the downregulation of vitamin D receptor. Hormone 705 
exocytosis caused by DON was found to be triggered by G-protein coupled receptor (GPCR)-706 
mediated Ca2
+
 signaling, using the murine neuroendocrine tumor STC-1 cell line (Zhou and 707 
Pestka, 2015). PAT has been evaluated against different endocrine disrupting models and no 708 
studies have revealed effects on reporter gene assays at the receptor level. 709 
A broad range of adverse health effects have been identified for mycotoxins in animals and 710 
humans, including hepatotoxicity, estrogenicity, immuno/haematotoxicity, nephrotoxicity or 711 
neurotoxicity. And some of them are recognized as genotoxic and/or carcinogenic, including 712 
AFB1, one of the most carcinogenic food contaminants in human diets and classified as 713 
carcinogenic to humans by the International Agency for Research on Cancer (Group 1), or 714 
OTA and FBs classified as possible carcinogens (Group 2B). AFB1 is a primary cause of 715 
human hepatocarcinoma, and in developing countries it acts synergistically with the hepatitis 716 
B virus infection.  717 
Mycotoxins also affects the intestinal barrier function, impairing the permeability and 718 
integrity of epithelial cells. Most prominent effects have been document for the trichothecene 719 
DON that may strongly impair the expression, localization and function of tight junction 720 
proteins which seal the epithelial monolayer and prevents the para-cellular diffusion of 721 
luminal antigens and microorganisms. Other trichotecenes including T-2 and HT-2 toxin and 722 
mycotoxins such as PAT or FB1 have been found to impair some of the physiological 723 
parameters that characterize the intestinal barrier function (Akbari et al., 2017). On this basis, 724 
it has been hypothesized the role of mycotoxins in the pathophysiology of chronic intestinal 725 
inflammatory diseases, such as inflammatory bowel disease, and in the prevalence of food 726 
allergies. 727 
The potential effect of mycotoxins in infant growth parameters has been recognised as a 728 
priority research gap, especially in developing countries, where the high occurrence of 729 
P O
 S 
T P
 R
 I N
 T
39 
 
mycotoxins comes together with the high prevalence of intrauterine growth restriction, infant 730 
and young stunting, underweight wasting. Whereas no epidemiological studies have been 731 
conducted to evaluate the associations between exposure to DON or ZEA and infant growth 732 
parameters, some studies that analysed exposure to AFs and FBs consistently found negative 733 
associations (Lombard et al., 2014). For instance, in African countries, strong dose response 734 
relationships were found between exposure in utero and/or early infancy to AFs and growth 735 
retardation, identified by reduced birth weight and/or low weight-for-age or height-for-age Z 736 
scores (Turner et al., 2013). 737 
Another important aspect to be considered is that many foods can present a simultaneous 738 
presence of different food contaminants, like mycotoxins, pesticides, heavy metals or 739 
radioactive particles (Kosalec et al., 2009). This multi-contamination can strongly modify the 740 
toxic effects of some of them resulting in a range of interactive effect as demonstrated by the 741 
simultaneous exposure of Caco-2 cells and HEK-293 kidney cells to cadmium and DON (Le 742 
et al., 2017). The toxicological evaluation of combinations of mycotoxins for the 743 
characterization of potential interactions is an emerging and very active field of research 744 
(Alassane-Kpembi et al., 2017). 745 
 746 
10. Mycotoxins as endocrine disruptors: case of ZEA and its derivatives 747 
The Endocrine Society’s Scientific Statement on Endocrine-Disrupting Chemicals (EDCs) 748 
says that an EDCs is “an exogenous chemical, or mixture of chemicals, that interferes with 749 
any aspect of hormone action” (Gore et al., 2015). The particular mechanism of actions of 750 
EDCs represent a novel paradigm in chemical risk assessment introducing new challenges 751 
related to ability of inducing biological effects at very low concentrations or the presence 752 
non-monotonic dose-responses. Hence, the emerging concern with EDCs emphasize the high 753 
interest of including mycotoxins, specially ZEA and its metabolites within the panel of 754 
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targeted analytes in exposome projects addressing hormone-dependent diseases. Despite the 755 
knowledge about the endocrine disrupting action of ZEA and its strong oestrogenic effects 756 
was identified decades ago (recently reviewed by Kowalska et al., 2016 and Metzler et al., 757 
2010), little attention has been paid by most researchers on EDCs who has extensively 758 
focused on industrial compounds such as bisphenol A or phthalates. Occurrence studies have 759 
demonstrated the pervasive presence of ZEA in cereal-based foods and the extended exposure 760 
among general population supporting that ZEA and specially the metabolite ZOL may be a 761 
relevant contributor on the total body burden of xenoestrogenic activity.  762 
In silico and in vitro studies have demonstrated the high affinity of ZEA and ZOL to bind and 763 
activate estrogen receptor, exhibiting potencies similar to 17-estradiol, and substantially 764 
higher than many industrial xenoestrogens such as bisphenol A (See Figure 1, based on 765 
Kuiper et al., 1998). Metabolite ZOL has non-estrogenic chemical structure but resembles 766 
that of 17-estradiol, exhibiting similar key contacts in the binding pocket of ER, resulting 767 
on high bioactivity (Delfosse et al., 2014; Balaguer et al., 2017). For that reason, a-ZON is 768 
recognised as one the most active xenoestrogens that can modulate ER activity at 769 
concentrations as low as 0.1 nM. (Balaguer et al., 2017). 770 
Figure 1. Relative transactivation activity of environmental endocrine disruptors for 771 
estrogenic receptor alpha created from data published by Kuiper et al., (1998). ZEA appears 772 
highlighted in red.  773 
 774 
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The related effects of ZEA and its derivatives in cells include the stimulation of growth of 775 
estrogen receptor-positive human breast cells, stimulation of cell cycle progression of MCF-7 776 
cells (Metzler et al., 2010). It has been also shown that ZEA may affect the metabolism of rat 777 
adipocytes, including the stimulation of basal lipolysis and reduced epinephrine stimulated 778 
lipolysis (Kandulska et al., 1999), suggesting ZEA also as a metabolic disruptor candidate.  779 
The endocrine disrupting effects of ZEA in animals includes the impairment of reproduction, 780 
uterotropic activity, hyperoestrogenism and inflammation of the vagina, endocrine-disruptive 781 
effects during gestation and neonatal life vaginal cornification, persistent estrus, reduced 782 
fertility, anovulation and decreased gonadotropic hormone output by the hypophysis among 783 
others (Kowalska et al., 2016; Metzler et al., 2010). Despite the large evidence suggesting the 784 
potential hormone disrupting effects of ZEA, few epidemiological studies have been 785 
conducted in humans to explore associations with estrogen-dependent diseases. Food 786 
contaminated with ZEA and its natural metabolites was associated with the development of 787 
precocious puberty, a risk factor for breast cancer (Gray et al., 2017). Furthermore, higher 788 
urinary ZEA levels, resulting from recent intake of beef or popcorn, were inversely 789 
associated with the onset of breast development (Bandera et al., 2011).  790 
 791 
11. Mycotoxins within the human exposome: challenges and opportunities 792 
The mycotoxins constitute a large group of chemicals that can be found regularly in foodstuff 793 
worldwide often resulting in the chronic exposures of low doses of complex mixtures of 794 
mycotoxins concurrently with industrial chemicals, phytochemicals and nutrients as 795 
represented in the Figure 2. The fast excretion and the low concentration levels of 796 
mycotoxins challenge their detection in biological samples, however current evidence 797 
demonstrate that major mycotoxins can be commonly found within the urine and blood 798 
chemical spectra (Marin et al., 2013). Dietary exposure assessment studies support that 799 
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infants and children are the most exposed population groups and the mycotoxin exposures 800 
continue through the entire life. Despite the relevance in terms of exposure and health effects, 801 
mycotoxins are often underscored and/or overlooked in epidemiological research as 802 
acknowledged by the visionary Christopher Wild (Wild and Gong, 2009), and no attention 803 
have received by major exposome projects launched in Europe, such as the impressive 804 
HELIX or EXPOsOMICS projects. 805 
Figure 2. Conceptual representation of the mycotoxin compartment within the human 806 
exposome framework including the sum of the most important mycotoxins that may found in 807 
the diet and respective forms or metabolites that are used as biomarkers in blood and urine. 808 
 809 
 810 
 811 
The novel exposome paradigm proposes a chemical-agnostic approach, that appears as an 812 
excellent opportunity to evaluate the role of mycotoxins in human health through more 813 
integrative approaches. This approach contrasts with the historical expertise of scientist that 814 
have been focusing on specific chemicals or group of chemicals. Hence, it looks like a big 815 
communicative and cross-talk effort will be required to efficiently optimize the already 816 
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available knowledge across disciplines. For instance, the mycotoxin compartment of human 817 
exposome, has been pretty well characterized for the main mycotoxins in terms of exposure 818 
and health effects, despite little is known about the rest of mycotoxins, modified forms and 819 
more emerging toxins. 820 
To date, most mycotoxin exposure assessment studies have been based on dietary modelling 821 
approaches although many limitations exist on these indirect exposure assessment methods, 822 
especially if we consider the uncertainties related to these modelling methods, and also the 823 
intra-individual or seasonal variability. Hence biomonitoring methods are considered the 824 
‘gold-standard’ to evaluate the individual exposures, however the field is still on its 825 
emergence and few biomarkers have been fully validated. The biomonitoring studies applied 826 
to mycotoxins have been mainly focused on surveillance of general population with 827 
regulatory or risk assessment purposes and few epidemiological studies have considered the 828 
evaluation of mycotoxins. Methodological approaches used to detect the mycotoxin 829 
biomarkers will strongly determine the performance (e.g. sensitivity), resulting on 830 
dramatically different results depending on the detection/quantification thresholds achieved 831 
(p.e. direct vs indirect methods). The development of reliable, accurate and sensitive 832 
multibiomarker methods to simultaneously characterize a large panel of mycotoxins, but also 833 
industrial pollutants, will strongly help to understand the potential associations between 834 
environment and health. On this sense, the application of non-targeted or semi-targeted 835 
HRMS metabolomic methods appears as a promising screening approach to identify exposure 836 
risk factors, and related biomarkers of biological perturbation (Warth et al., 2017). It appears 837 
also as a great opportunity to explore the underlying toxicological effects of mycotoxins in 838 
humans. Coupling other OMICs platforms for the identification of endogenous chemical 839 
signatures we may gain access to early biomarkers of health effects and biological 840 
perturbation triggered by mycotoxins. In any case, a list of challenges associated with the 841 
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accurate determination of biomarkers of non-persistent pollutants exposure applies directly to 842 
the mycotoxins, including the high intra- and inter-day individual variability, requiring 843 
repeated sampling protocols to avoid the exposure misclassification (Perrier et al., 2016). 844 
Additionally, specific issues related to mycotoxins such as the variability related to seasonal 845 
or weather influences on mycotoxin productions will challenge the estimations of individual 846 
trajectories. 847 
The simultaneous determination of mixtures of mycotoxins within more complex cocktails of 848 
environmental pollutants will allow address major research gaps related to mixture effects. A 849 
growing interest on the effect of mycotoxin mixtures have led toxicologist dosing binary and 850 
tertiary combinations of mycotoxins, sometimes with little similarities on mechanism of 851 
action, whereas few or non-studies have evaluated the simultaneous effect of mycotoxins 852 
with other environmental pollutants with similar biological actions (e.g. the xenoestrogens 853 
bisphenol A and ZEA). 854 
  855 
12. Concluding remarks 856 
In the present review we have shown that mycotoxins maybe commonly found at high 857 
concentrations in blood and urine from individuals from developing countries, but also 858 
frequently found at moderate or low concentrations in developed regions. For instance, it has 859 
been estimated that 500 million of the poorest people in sub-Saharan Africa, Latin America, 860 
and Asia are exposed to mycotoxins at levels that substantially increase mortality and severe 861 
diseases (Wild and Gong, 2010). The health effects of mycotoxins are very wide, targeting 862 
different toxicological endpoints, biological functions and have been related with multiple 863 
diseases. To date, few studies have been able to demonstrate consistent associations of health 864 
effects in humans relying most of studies on animal or in vitro settings.  865 
P O
 S 
T P
 R
 I N
 T
45 
 
We strongly believe that mycotoxins represent a relevant component of the human exposome 866 
and that exposome-based projects aiming to explore the role of chemical exposome on human 867 
health, should strongly consider the mycotoxins within the panel chemical candidates.  868 
Whereas industrial chemicals may be banned and set out of the market, mycotoxins will not 869 
be completely removed of raw foods and food items intended for human consumption. Even 870 
with very stringent regulations, humans will continuously be exposed to low level of 871 
mycotoxins whose combined effect and their combined effect with other environmental 872 
exposures whose effects are completely unknown. As we have shown in this document, 873 
currently there are available robust and accurate analytical methods that allow the 874 
identification and characterization of multiple mycotoxins and/or their metabolites in most 875 
common biological samples, allowing the direct implementation in epidemiological research.  876 
Overall, we acknowledge that the exposome projects will be a great opportunity to better 877 
translate the knowledge generated on mycotoxicology during the past decades in 878 
environmental health. Conversely, these new approaches may be an excellent opportunity to 879 
fill many research gaps on mycotoxins research as the identification of associations 880 
mycotoxins with human health, elucidation of join effect with other environmental exposures 881 
or the decipher of underlying molecular mechanisms by using advanced OMICs technologies.  882 
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